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A B S T R A C T
The complement system is well known for its role in innate immunity and in maintenance of tissue homeostasis,
providing a first line of defence against infection and playing a key role in flagging apoptotic cells and debris for
disposal. Unfortunately complement also contributes to pathogenesis of a number of diseases; in some cases
driving pathology, and in others amplifying or exacerbating the inflammatory and damaging impact of non-
complement disease triggers. The role of complement in pathogenesis of an expanding number of diseases has
driven industry and academia alike to develop an impressive arsenal of anti-complement drugs which target
different proteins and functions of the complement cascade. Evidence from genetic and biochemical analyses,
combined with improved identification of complement biomarkers and supportive data from sophisticated an-
imal models of disease, has driven a drug development landscape in which the indications selected for clinical
trial cluster in three ‘target’ tissues: the kidney, eye and vasculature. While the disease triggers may differ,
complement activation and amplification is a common feature in many diseases which affect these three tissues.
An abundance of drugs are in clinical development, some show favourable progression whereas others experi-
ence significant challenges. However, these hurdles in themselves drive an ever-evolving portfolio of ‘next-
generation’ drugs with improved pharmacokinetic and pharmacodynamics properties. In this review we discuss
the indications which are in the drug development ‘spotlight’ and review the relevant indication validation
criteria. We present current progress in clinical trials, highlighting successes and difficulties, and look forward to
approval of a wide selection of drugs for use in man which give clinicians choice in mechanistic target, modality
and route of delivery.
1. Introduction
Scientists have strived for decades to develop drugs to treat com-
plement-mediated diseases. By the end of the 20th century, many anti-
complement agents had shown promise in vitro and in animal models,
but few drug candidates had progressed to man and those that did were
not developed further. Among the preclinical molecules being tested at
that time were antibodies against complement components which
blocked function, such as anti-mouse C5 and anti-human C5 (Frei et al.,
1987; Thomas et al., 1996); their function in vitro and efficacy in animal
models of disease was readily established (De Vries et al., 2003; Huugen
et al., 2007; Ravirajan et al., 2004). By the early 21st century the hu-
manised anti-human C5 monoclonal antibody, eculizumab, was pro-
gressing through clinical development and, in 2007, it was approved by
the FDA for use in the rare but devastating disease: paroxysmal noc-
turnal haemoglobinuria (PNH) (Brodsky et al., 2008; Hillmen et al.,
2006; Rother et al., 2007). Clinical validation of anti-complement
therapy was a landmark in complement drug discovery; this break-
through, combined with ground-breaking data emerging from genome
wide association studies (GWAS), which demonstrated key roles of
complement in wide-spread disease (Edwards et al., 2005; Hageman
et al., 2005; Haines et al., 2005; Klein et al., 2005), drove a renaissance
in anti-complement drug discovery. This has brought us to the current
day with many new drugs progressing through late stage clinical de-
velopment and numerous others in discovery or preclinical stages
(Morgan and Harris, 2015; Ricklin et al., 2018).
There are a number of challenges associated with developing drugs
against complement, including the sheer quantity of circulating protein,
the central role of complement in fighting infection, and the identifi-
cation of an appropriate target and an appropriate disease, or drug
indication (Harris, 2018). In a number of diseases, complement plays a
driving role in pathogenesis, whereas in others, complement is an ‘ex-
acerbator’ of disease, inducing increased pathology initiated by a dif-
ferent disease trigger, thus driving inflammation and tissue damage
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(Ricklin et al., 2016). PNH is an example of the former, where a defi-
ciency in complement regulators renders erythrocytes and other cells,
such as platelets, susceptible to complement attack and subsequent lysis
or activation (Hill et al., 2017; Hillmen et al., 1992). In this disease,
identification of an appropriate drug target is less challenging as the
pathogenic mechanism is clear; inhibition of MAC formation using
eculizumab prevents intravascular haemolysis and rapidly improves
quality of life for patients. The choice of target may not be so clear in
other potential indications, and even in PNH, the quest for optimal
target selection continues and many drug candidates are currently
being evaluated. In the last decade, technological advances have ac-
celerated genetic and biochemical analyses to the point where under-
standing of intricate disease mechanisms is facilitated and rationale for
specific indication selection is strengthened. The number of potential
targets in the complement system is expanding as the role of comple-
ment beyond lysis and in cross-talk with other biological systems, such
as coagulation, is becoming clearer. Companies and academic institutes
are developing drugs which target every pathway in the system and
these drugs include small molecules, peptides, biologics, antibodies and
DNA-based therapeutics.
Due to the cascade nature of complement and the large number of
proteins involved, selecting distinct points of intervention may result in
different therapeutic effects. For a detailed insight into the function of
the complement system we refer to recent reviews on the topic and only
provide a brief overview of the system here (Fig. 1) (Holers, 2014;
Ricklin and Lambris, 2013). In most cases, complement is triggered by
foreign or altered surfaces. In the classical pathway, recognition of
immune complexes (and other non-immunoglobulin moieties) by C1q
activates the associated serine proteases, C1r and C1s, which cleave the
plasma proteins C2 and C4 to form a C3 convertase complex (C4b2a) on
the activating surface. The same result is achieved when pattern re-
cognition proteins of the lectin pathway (mannose-binding lectin
[MBL], ficolins, collectins) bind to pathogen carbohydrate patterns and
induce MBL-associated serine proteases to cleave C2/C4. The generated
C3 convertases activate C3, resulting in the deposition of C3b (opso-
nisation) and the release of C3a. Through interplay with the proteases
factor B and D (FB, FD), surface-bound C3b forms additional C3 con-
vertases. The alternative pathway is primarily responsible for the rapid
amplification of opsonisation on unprotected cells and also provides a
means of constant background activity. The continuous deposition of
C3b and stabilisation of convertases by properdin leads to a gradual
shift to the assembly of C5 convertases, which cleave C5. Whereas the
released C5a is among the strongest chemoattractants and pro-in-
flammatory modulators, primarily via binding to C5a receptor 1
(C5aR1), the C5b fragment can induce the assembly of membrane at-
tack complexes (MAC) that damage or induce lysis of attacked cells. To
Fig. 1. Activation and control of the
complement cascade. Activated C3
(C3b) deposited on a target surface can
bind factor B (FB) which is activated by
factor D (FD) to form the C3-cleaving
enzyme (convertase) C3bBb. This en-
zyme cleaves further C3 to C3a and
C3b, the latter decorates the surface
(opsonisation) or binds the C3 con-
vertase to form the C5 convertase,
C3bBbC3b. Both the C3 and C5 con-
vertase can be stabilised by properdin
(P). Activation of the classical and
lectin pathways results in covalent
binding of C4b to the target surface, this
binds C2 which is activated by C1r/s or
the mannose-binding lectin-associated
serine proteases (MASPs) to form the
classical/lectin C3 convertase, C4b2a.
Further cleavage of C3 to C3b results in
formation of the C5 convertase,
C4b2a3b. Cleavage of C5 marks the
start of the lytic, or terminal, pathway.
C5a is highly proinflammatory, while
C5b binds C6 to initiate formation of
the MAC (membrane attack complex);
C7, C8 and multiple molecules of C9
bind to C5b6 to form the transmem-
brane pore. There are many proteins
which control the cascade, either at the
initiation level (C1-inhibitor [C1INH]
inhibits C1r/s and the MASPs), or at the
level of C3b and the convertase en-
zymes (including CD55, CD46, CD35,
factor H [FH], factor I [FI] and C4-
binding protein [C4BP]). Various pro-
teins either inhibit C9 polymerisation
and thus formation of the MAC on the
membrane (CD59) or render it soluble
(clusterin, vitronectin), resulting in so-
luble terminal complement complexes.
*Tickover and contact with foreign
surfaces may generate hydrolysed C3,
i.e. C3(H2O), which shares structural and functional properties with C3b. **Alongside mannose-binding lectin (MBL), the lectin pathway may also be initiated by
ficolins and collectins.
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control complement activation and the deleterious effector functions,
human cells engage a number of potent regulators. For example, the
initiation of the classical and lectin pathways is controlled by C1 es-
terase inhibitor (C1-INH). Owing to the central role of the convertases,
an entire panel of regulators is involved in keeping these enzyme
complexes in check. Membrane-bound (CD35, CD46, CD55) or soluble
(C4b-binding protein [C4BP], factor H [FH]) inhibitors disassemble the
convertases and/or enable the degradation of C3b by factor I (FI). Im-
portantly, C3b and its cleavage fragments (iC3b, C3dg) are involved in
phagocytic or adaptive immune signalling via binding to complement
receptors (CR). Finally, the assembly of MAC is prevented by the
membrane regulator CD59. Whereas the balance between activating
and regulating processes enables an efficient immune surveillance, ex-
cessive activation or insufficient regulation can contribute to clinical
complications (Rodriguez de Cordoba et al., 2012).
Complement is implicated in a wide spectrum of diseases affecting
multiple organs. The current drug development landscape illustrates
that the same drug is being applied to multiple diseases which affect a
number of different organs (Fig. 2).The picture is dominated by diseases
affecting the vasculature, the kidney and the eye. In the haematological
indications, PNH, although very rare, is a very attractive indication to
select as there is already clinical validation (with eculizumab) and the
appropriate drug targets are understood. Diseases of the kidney are also
prominent in the drug development path, in many of these pathologies
there is unmet need with no prospect of long-term therapy. Aside from
this, the pathogenic mechanisms have become clear in recent years and
in some diseases, such as C3 glomerulopathy (C3G) and atypical hae-
molytic uraemic syndrome (aHUS), the disease is clearly driven by the
alternative pathway of complement, thus facilitating selection of drug
target. The clear genetic association between the alternative pathway
and the wide-spread disease, age-related macular degeneration (AMD),
has made this a favoured indication, and anti-complement drugs tar-
geting the eye feature predominantly in company pipelines.
Treating these and other conditions with anti-complement therapy is
not without its challenges, which include amount and frequency of drug
dose, and selection of local (if possible) or systemic delivery. In this re-
view, we focus on the three tissues highlighted above, the vasculature,
kidney and eye, and we summarise the indications which are currently in
clinical trial(s). We provide the rationale for indication selection and
describe the progress in clinical development. Where possible, we high-
light the successes and difficulties, such as dose or delivery, which pro-
vide additional insight into the challenges of drug development. Only by
learning from current clinical trials in man, can we hope to develop the
best ‘tool box’ of anti-complement drugs for the future.
2. The kidney
2.1. Renal indications involving complement
The kidney is highly susceptible to a large number of complement-
mediated disorders, and renal diseases as target indications have been
particularly attractive for drug companies. This is because in several
diseases, such as aHUS and C3G, the pathogenic mechanisms are well-
defined and the contribution of complement is prominent. Deposition of
activated complement components is evident in most cases of renal
diseases, sometimes in association with well-recognised classical trig-
gers, such as antibodies, but frequently without any apparent cause
until further diagnostic clues are scrutinised. The susceptibility of the
kidney to complement-mediated disease suggests that its anatomy or
function make it particularly sensitive to complement dysregulation
(Fig. 3) (Ricklin et al., 2018; Thurman, 2015). The renal diseases, or
indications, which have been of most interest to companies and aca-
demics developing anti-complement drugs are outlined below, together
with a review of current clinical developments in that field.
Atypical haemolytic uremic syndrome (aHUS) is a disease char-
acterised by a classical triad of thrombocytopenia, microangiopathic
haemolytic anaemia and acute kidney injury (Sethi and Fervenza,
2014). In approximately 60% of patients the root cause has been linked
to genetic abnormalities in genes encoding complement activating and/
or control proteins and in a further 10% of patients to autoantibodies
which bind functional domains of FH (see Table 1). Other non-com-
plement genes have been associated with aHUS, such as diacylglycerol
kinase epsilon (DGKE), but their mechanistic role in pathogenesis has
not yet been elucidated (Lemaire et al., 2013). In the complement-
mediated form of the disease, the alternative pathway amplification
loop of the complement system is usually hyperactive and the focus of
attack is at the surface of endothelial cells within the kidney which
leads to cell activation and dysfunction, swelling and damage (Fig. 3c)
(Kavanagh and Goodship, 2010; Rodriguez de Cordoba et al., 2014,
2012). Thrombus formation within the glomeruli and capillaries of the
kidney are evident in aHUS, and while it is likely that complement
activation fragments such as C5a and MAC drive this process, sy-
nergistic effects of genetic variants within the coagulation system have
not been ruled out (Kavanagh and Goodship, 2011). In aHUS, many
patients carry one normal and one mutant form of the complement gene
and frequently these single gene mutations are not completely pene-
trant for disease. Concurrence of multiple risk factors is commonly re-
quired for disease manifestation; these include common and rare var-
iations in complement genes, and other factors such as pregnancy,
Fig. 2. The development pipeline for
anti-complement drugs in the
kidney, eye and vasculature.
Complement drugs in preclinical and
clinical stages of development are
shown, and their stage of testing in
each tissue is indicated. The schematic
is based on company press releases and
corporate presentations (as of April
2018), publications and conference
proceedings. The mechanism or com-
plement pathway for each drug is in-
dicated by colour code: green, initia-
tion of complement; blue, amplification
loop; red, C5 and terminal pathway. *
Lampalizumab has been evaluated in
two phase 3 trials, both of which were
recently discontinued; ** The approved
indication for C1-INH is a disorder not
primarily driven by complement (i.e.
hereditary angioedema).
Adapted from Ricklin et al. (2018).
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Fig. 3. Kidney structure and pathogenic mechanism in aHUS. (a) A healthy kidney has approximately 1 million nephrons, these are the microscopic and
functional unit of the kidney, each comprising a renal corpuscle and tubule. (b) The renal corpuscle is comprised of a glomerulus, which holds a network of capillaries
supported by mesangial cells, encapsulated within the Bowman’s capsule. The Bowman’s capsule serves as a collecting space for fluid filtered through the glomerulus.
Blood is filtered as it passes through three layers: the capillary endothelial cells, the glomerular basement membrane and the foot processes of the podocytes, the cells
which line the capsule. The glomerular basement membrane (GBM) forms at the interface between the endothelial cells and podocytes. The glomerular capillary wall
determines the size and charge selective features of the glomerular barrier to macromolecules. Complement attack and/or deposition occurs at many sites within the
glomerulus and tubule, including the GBM, the mesangium, around the foot processes of the podocytes, and at sub-endothelial and sub-epithelial sites. Sites of
pathology in different indications are described in the main text; inappropriate complement attack impairs the ability of the kidney to filter blood and produce urine.
(c) In aHUS, complement control at the surface of the endothelial cells is defective. The pathway most impacted is the alternative pathway, triggered by FB binding
C3b to form the proenzyme C3bB. FD cleaves FB resulting in the convertase C3bBb which generates further C3b and ultimately the C5 convertase, C3bBbC3b. In
health, control proteins such as CD46, FH and FI control the C3 and C5 convertase enzymes at the cell surface, but in aHUS these mechanisms are impacted by
autoantibodies and gene mutations resulting in excessive production of the activation products, C5a and MAC. The anaphylatoxin, C5a, activates platelets and
immune cells, whereas MAC activates endothelial cells and causes physical damage, resulting in endothelial swelling. Activated endothelial cells also express
proinflammatory mediators and adhesion molecules. Subsequent microthrombi forming in the capillaries results in platelet consumption, vascular occlusion and
mechanical haemolysis of erythrocytes. Eculizumab binds C5 and prevents cleavage by the convertase, thus preventing formation of both C5a and MAC and blocking
downstream pathogenic events such as thrombus formation and endothelial cell activation and damage. NO, Nitric oxide; PGI2, prostaglandin I2; TF, tissue factor;
vWF, von Willebrand factor. Part (c) reproduced with permission from the National Renal Complement Therapeutics Centre 2016/2017 annual report (http://www.
atypicalhus.co.uk/).
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infection or use of certain drugs which may in turn impact systemic
complement activity (Harris et al., 2012; Rodriguez de Cordoba et al.,
2012). There are studies suggesting that the release of heme during
aHUS-related hemolysis further induces an activation of the alternative
pathway on endothelial cells, thereby providing a ‘secondary hit’ that
exacerbates tissue damage (Frimat et al., 2013).
Eculizumab binds complement component C5, preventing its clea-
vage and thus blocking formation of both C5a and MAC; it was ap-
proved for aHUS by the FDA in 2011 and its use has been life-changing,
relieving further attack on the kidney soon after administration and
preventing progression to end-stage renal failure if used early enough in
the disease (Wong et al., 2013). It is not yet clear whether C5a or MAC,
or in fact both, are responsible for the pathogenic role of complement; it
may therefore be interesting to see whether drugs targeting C5a-
mediated signalling currently in development (see below) will sig-
nificantly reduce disease progression by themselves. Meanwhile, as
eculizumab prevents formation of all activation products downstream
of the C5 convertase, it has a profound therapeutic impact and has
quickly developed into the gold standard of aHUS treatment in many
markets. Risks associated with C5 blockade include meningococcal in-
fection which is managed with prophylactic vaccination and, in some
countries, additional use of prophylactic antibiotics. Drawbacks to
eculizumab include high cost that restricts drug availability in several
countries, high dose (1200mg for an adult) necessitating intravenous
infusion every other week, and breakthrough symptoms when for some
reason, such as an acute phase episode, complement C5 levels are in-
creased (Peffault de Latour et al., 2015; Schutte et al., 1975). Although
aHUS is rare, 0.42 per million population (UK) (Sheerin et al., 2016),
and well-managed through administration of eculizumab, it remains of
interest to drug companies as new and improved therapies might limit
the drawbacks outlined above such as route and frequency of admin-
istration. Due to the extreme rarity of the disease, recruitment to clin-
ical trials may be difficult in countries where eculizumab is available
for treatment. Never-the-less clinical trials are ongoing and in years to
come clinicians treating patients with aHUS may find that there is a
selection of drugs approved and available with varying modes of action
and routes of administration.
C3 glomerulopathy, C3G, is also rare and encompasses a hetero-
geneous group of syndromes encompassing dense deposit disease
(DDD) and C3 glomerulonephritis (C3GN) (Iatropoulos et al., 2018;
Pickering et al., 2013). As with aHUS, C3G is a disease in which the
complement system is dysregulated, typically within the amplification
loop. Unlike in aHUS, the dysregulation usually affects fluid phase ac-
tivation (Martinez-Barricarte et al., 2010). It is clear that systemic ac-
tivation of complement leads to high levels of complement deposition
in the kidney, particularly at the glomerular basement membrane
(GBM), but whether systemic or local activation of C3 is causative is
unclear. Deletion of FH in mice leads to spontaneous disease, and the
normal phenotype can be restored by reinstating control of the ampli-
fication loop either systemically or locally (see Table 1). While the
means of dysregulation are heterogeneous, the attraction of this in-
dication for clinical trials is that alternative pathway dysregulation is
central to the pathogenic process, and within that pathway and the
amplification loop, blockade of one of many drug targets will sig-
nificantly impede activation (Table 1). Due to the abundance of com-
plement biomarkers of disease, there is potential to seek mechanistic
signals in addition to clinical endpoints to confirm that the target is
engaged. As with aHUS, mutations in genes encoding complement ac-
tivating and control proteins are strongly associated with diseases, in
addition to autoantibodies, particularly nephritic factors (NeF)
(Iatropoulos et al., 2018; Servais et al., 2012). The latter typically bind
neoepitopes on the C3 or C5 convertase causing dysregulation of those
enzymes, although antibodies to FH, FB and C3b have also been de-
scribed (Paixao-Cavalcante et al., 2012; Skerka et al., 2009). While their
causative nature is unclear, NeF are present in a high proportion of
patients with DDD. DDD and C3GN are primarily distinguished by
histological parameters and other, more subtle, changes in complement
biomarkers. Dysregulation at the level of C3 is more common in both
conditions, while over-activation at the level of C5 may associate more
with C3GN (Tanuma et al., 1990). Various strategies, such as im-
munosuppression or plasma exchange, may help patients with C3G, but
to date there is no treatment to prevent end stage renal disease. There
are limited case reports and trial data pertaining to the use of eculi-
zumab in C3G, but outcomes are variable and are likely linked to the
extent of C5 dysregulation in an individual patient (Zuber et al., 2012).
Immune complexes in the kidney are notably absent in aHUS and
C3G, but are present in other diseases of the kidney. In immune
complex glomerulonephritis (IC-MPGN), immune complexes activate
the classical pathway and deposits of activated C3 and immunoglobulin
are found in the kidney. The disease is heterogeneous with variable
presence or absence of complement gene mutations, autoantibodies and
complement abnormalities in the circulation (Table 1) (Iatropoulos
et al., 2018). Although considered a disease driven by immune com-
plexes, it is intriguing that NeF are present in a high proportion of
patients and mutations in alternative pathway genes have been de-
tected. This suggests that dysregulation of the amplification loop may
play a role in disease pathogenesis, perhaps ‘tipping the balance’ in an
already compromised state of complement control. Other diseases
linked to abnormal antibody deposition in the kidney include IgA ne-
phropathy, typified by deposition of IgA in the kidney along with signs
of lectin and alternative pathway activation (Table 1) (Daha and van
Kooten, 2016). It is thought that abnormal glycosylation of the IgA
molecule leads to recognition by anti-glycan antibodies. Mannan-
binding lectin (MBL) accumulates in the glomeruli of some patients
and, together with C4d deposition, correlate with worse outcome
(Espinosa et al., 2014); these data together with early signs that clinical
inhibition of the lectin pathway (anti-MASP2, Omeros; see below)
might have therapeutic benefit in these patients, suggest that the lectin
pathway plays a role in driving pathology. Genetic deficiency of the
complement factor H-related proteins 1 and 3 (FHR-1, -3) associates
with lowered risk of disease (Gharavi et al., 2011), thereby also im-
plicating a contribution of the alternative pathway as the FHRs prevent
localisation of the regulator FH, which controls the alternative pathway
C3 and C5 convertases (Goicoechea de Jorge et al., 2013; Tortajada
et al., 2013).
Lupus nephritis (LN) is a common clinical manifestation and cause
of morbidity in systemic lupus erythematosus (SLE), in which immune
complexes deposit in the kidney causing complement activation, renal
cell damage and thrombotic microangiopathy (TMA) (Yu et al., 2017).
Up to 50% of patients with SLE will have clinically evident kidney
disease at presentation; during follow-up, renal involvement occurs in
up to 75% of patients (Bomback et al., 2016). Complement plays an
intriguing dual role in SLE pathogenesis. While deficiency of classical
pathway components C1, C4 and C2 is high risk for SLE, probably due
to a failure in clearance of cell debris and immune complexes (Pickering
et al., 2000; Walport, 2002), complement is required to drive in-
flammation and tissue damage in active disease, often leading to low
levels of the central components, C3 and C4, due to secondary con-
sumption (Table 1). The exact role and mechanism of complement-
mediated damage in LN is unclear. Immune deposits usually consist of
anti-double-stranded DNA antibodies targeting nucleosomal antigens
and antibodies binding chromatin in the mesangium and GBM; im-
mune-histologic studies demonstrate immunoglobulin, C1q and C3
deposition. Depending on the site of immune complex formation, influx
of inflammatory cells can vary, histologic analysis reveals proliferative
glomerulonephritis at different sites within the glomerulus, or a mem-
branous nephropathy-type appearance (Bomback et al., 2016). Renal
manifestations are also common in the pauci-immune glomerulone-
phritis, ANCA (anti-neutrophil cytoplasmic antibody)-associated
vasculitis (AAV) (Manenti et al., 2015). As AAV is pauci-immune in
nature, it was originally thought that antibody and complement played
little role in pathogenesis of the disease. However, availability of
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improved reagents to detect complement in tissues, coupled with ele-
gant mechanistic studies, demonstrate a clear role of the alternative
pathway and C5a in driving disease. Neutrophil priming leads to in-
creased adhesiveness of cells to walls of small blood vessels in many
organs; intracellular proteins such as myeloperoxidase (MPO) become
surface-localised, and autoantibodies to MPO activate complement
leading to release of C5a (Jennette et al., 2013; Noone et al., 2018).
This binds back to C5a receptor 1 (C5aR1) on neutrophils, further ac-
tivating the cells and setting up a vicious cycle of inflammation. In AAV,
levels of alternative and terminal pathway activation fragments are
elevated, and renal biopsies frequently indicate activation of the al-
ternative pathway (Table 1). Therapeutically interfering with C5a-
mediated signalling might have benefit in AAV as evidenced by the
positive phase 2 outcome from trial of avacopan (see below); treatment
with this C5aR1 antagonist was shown to have a steroid-sparing effect
(Chen et al., 2017; Jayne et al., 2017). Membranous nephropathy
(MN) is another renal indication driven by immunoglobulins, it is
commonly associated with antibodies against M-type phospholipase A2
receptor (PLA2R), often of IgG4 isotype (Beck et al., 2009). While it is
clear that primary MN is associated with complement activation, the
exact mechanism and role of the IgG4 antibodies have yet to be eluci-
dated as they are typically non-complement activating. In MN, anti-
bodies permeate the GBM and form immune complexes on podocyte
membranes. Subsequent complement activation, probably sub-lytic,
leads to cellular damage and thickening of the GBM. Complement de-
posits of activated C3, C4 and MAC are evident in the absence of C1q
(distinguishing from secondary forms of MN) (Ma et al., 2013); iden-
tification of MBL in renal biopsies suggests that the lectin pathway
might be responsible for complement deposition (Table 1).
Various complications of renal transplant have been the focus of
numerous clinical trials with limited success to date. However, the
potential to prolong transplant life, and the huge benefit to patients by
preventing rejection, keeps this indication in the spotlight. Ischemia/
reperfusion (I/R) injury is a common cause of acute kidney injury
(AKI) following transplant resulting in delayed graft function.
Complement activation associated with I/R injury tends to manifest in
the tubulointerstitium as evidenced by C3 deposition in the tubular
basement membrane in humans and animal models - it is likely that the
alternative and terminal complement pathways play a key role in pa-
thogenesis (McCullough et al., 2013; Thurman et al., 2005). Acute
tubular necrosis due to ischemia is one of the most common causes of
renal failure in man. Localisation of injury within the tubule may be a
result of disruption of the apical-basolateral organization of the tubular
epithelium due to ischemia, and access of proteins which are normally
restricted to the apical side. It is highly likely that short-term ameli-
oration of the I/R insult will go a long way to improving outcome
following renal transplant. Antibody-mediated rejection (AMR) is
another key factor restricting success of transplantation. Donor-specific
antibodies (DSA) due to HLA/ABO mismatch can cause acute rejection
within hours with massive activation of complement and tissue necrosis
(Stegall et al., 2012). Effective pre-screening can minimise risk, but
there is potential for anti-complement agents to prevent complement
activation for a sufficient period to result in organ accommodation,
particularly in cases such as ABO mismatch (Fiane et al., 1999). The
role of de novo DSAs which develop post-transplant in chronic AMR is
not clear, although emerging evidence implicates C1q and complement
in driving pathology which will eventually result in loss of transplant
function (Yell et al., 2015). Whether or not complement inhibition will
be of benefit in chronic AMR remains to be investigated.
All of the diseases listed above have been, or are, in clinical trials for
anti-complement therapy. In a number of these indications, the me-
chanisms of complement dysregulation and/or inappropriate activa-
tion, are well-characterised. Clearly these well-defined diseases are of
interest to companies developing drugs; exploratory biomarkers are
obvious and relatively simple to monitor and potentially correlate with
clinical endpoints. In other indications, the mechanism might not be so
clear, but a growing body of evidence is highly suggestive of key in-
volvement of the complement system. Some drugs in clinical develop-
ment hit multiple pathways (such as C3 inhibitors), thereby having
potential for those indications where the exact causative factor is un-
known, but the pathogenic entity lies between a well-defined trigger
and an endpoint of complement deposition or activation in the tissue.
Much of the information discussed below is gleaned from company
websites and conference proceedings and these are cited where prac-
tical and possible; the reader is referred to several recent reviews which
highlight and discuss the extensive number of drugs which are in pre-
clinical and clinical development by different companies (Morgan and
Harris, 2015; Ricklin et al., 2018).
2.2. Clinical development of drugs targeting the alternative pathway
amplification loop in renal disease
The amplification loop of the alternative pathway is a major driving
force behind complement activation and often determines the onset of
C5 convertase formation, thereby initiating subsequent C5 cleavage and
terminal pathway activation. Even in diseases where pathological me-
chanisms are mediated by the lectin or classical pathways, blockade of
the alternative pathway can frequently provide therapeutic benefit.
Intervention in the amplification loop is considered an attractive pro-
position in drug development as the upstream lectin and classical
pathways are functional and can fight infection through opsonopha-
gocytosis; at the same time damage-driven opsonisation is reduced and,
downstream, the terminal pathway is critically impacted, restricting
production of the proinflammatory mediators C5a and MAC.
Within the amplification loop there are multiple targets, C3 (or
C3b), FB, FD and properdin, and all have been targeted in drug de-
velopment (Ricklin and Lambris, 2016). Various antibodies have been
developed which bind activated C3b, possibly to lower dose compared
to blocking native C3, but to the best of our knowledge, none remain in
clinical development (DiLillo et al., 2006; Katschke et al., 2009). A
blocking agent against properdin has also been reported by Novartis;
this antibody, termed CLG561, is not in trial for renal disease. Two
agents are currently in clinical trial which directly target C3 activation
in renal indications. They are both based on the C3 inhibitor comp-
statin, which binds to native C3 and prevents its activation by C3
convertases (Ricklin and Lambris, 2008). AMY-101 is under develop-
ment by Amyndas for multiple indications (http://amyndas.com/),
which include C3G and ABO mismatch kidney transplant. AMY-101 is a
latest-generation compstatin analogue with improved affinity and
pharmacokinetic (PK) properties, including potential for administration
via the subcutaneous (SC) route (Mastellos et al., 2015; Ricklin and
Lambris, 2008). The phase 1 trial (NCT03316521) results in healthy
volunteers were announced in December 2017 stating that AMY-101
could be administered SC every 48 h and maintain effective C3
blockade with a satisfactory safety profile (Amyndas Press Release,
2017). AMY-101 has been granted orphan designation for C3G and PNH
by EMA and FDA and phase 1b/2 clinical trials are imminent. A second
compstatin-derived drug candidate, APL-2, is based on an earlier ana-
logue of the C3 inhibitor, which had originally been licenced to Po-
tentia. In view of the weaker target-binding when compared to AMY-
101, it has been derivatised using PEG to link two cyclic peptide moi-
eties to provide longer half-life (http://www.apellis.com/). APL-2 also
demonstrated satisfactory safety profile in phase 1, which largely alle-
viated prior fears that systemic inhibition of the complement system
due to blockade of its central component, C3, puts patients at risk of
severe infection; all subjects were vaccinated against Neisseria me-
ningitidis types A, C, W, Y and B, Streptococcus pneumoniae and Hae-
mophilus influenzae Type B (Hib). In total 51 subjects were enrolled in
placebo-controlled studies; twenty-four subjects received APL-2 as a
single dose (top dose 1440mg) and sixteen subjects received repeated
daily doses of APL-2 for a month (top dose at 270mg/day). Alternative
pathway haemolytic activity was impacted following a single dose of
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1440mg APL-2 and following multiple daily doses of 180 and 270mg
(Grossi et al., 2016). These dosing levels were required due to the high
plasma concentration of the target, C3 (> 1mg/ml), nonetheless, both
studies concluded that pharmacological doses of APL-2 were safe and
well tolerated and that APL-2's PK/PD profile supported daily SC ad-
ministration (Apellis Press Release, 2016). The dosing regime of 180mg
or 270mg daily (SC) is current protocol for phase 1 studies in PNH
(NCT02588833). While the lead indications, PNH and AMD, are de-
scribed below, APL-2 is currently being trialled in patients with a
variety of biopsy and biomarker-confirmed renal diseases, including
IgA nephropathy, LN, MN, C3GN and DDD (Phase 2, NCT03453619;
first posted to ClinicalTrials.gov March 2018). The drug is being ad-
ministered once a day for 16 weeks with a 6 month safety follow-up and
a primary endpoint of change in baseline proteinuria at 16 weeks.
While these trials will provide long-awaited insight into the efficacy and
safety of C3 blockade, it will be interesting to see in which disease in-
dications PEGylation proves beneficial. Whereas the addition of PEG
units may confer important benefits concerning solubility and/or PK,
high PEG concentrations may potentially influence the safety profile,
and short-lived complement inhibitors may allow rapid restoration of
complement activity in case of adverse events (Ivens et al., 2015;
Risitano et al., 2014).
A sea change in anti-complement therapy is marked by the recent
development of orally bioavailable anti-complement drugs. Two small
molecule (SM) drugs with activity on the amplification loop have been
developed by Achillion (ACH-4471; http://www.achillion.com/) and
Novartis (LPN023; https://www.novartis.com/). The Novartis agent,
LPN023, binds the active site of FB and thus inhibits the convertase and
C3 cleavage. The phase 2a/2b dose ranging study was first posted to
ClinicalTrials.gov in December 2017 (NCT03373461), marking the start
of a long-awaited trial. The agent will be taken twice daily (BID) in
patients with IgA nephropathy to establish clinical proof-of-concept and
dose. The change in urine protein to creatinine concentration (from
original baseline measurement) is being monitored as a primary end-
point; secondary outcomes probe renal function in more depth and
examine drug PK and impact on the complement alternative pathway
through measurement of plasma Bb and sC5b-9. As with APL-2, all
patients receive triple vaccination prior to receiving the drug.
The second orally-bioavailable drug, the FD inhibitor ACH-4771,
has been developed by Achillion. By blocking the catalytic site of FD,
the drug prevents formation of functional alternative pathway C3
convertases. In phase 1 studies, ACH-4771 was administered twice a
day at a single dose of 1200mg, delivering almost complete inhibition
of alternative-pathway activity in ex vivo blood samples at 24 h
(Achillion Presentation, 2016). While further phase 1 studies assess PK
of modified formulations (NCT03384186), ACH-4771 is being ad-
ministered three times daily (TID) with an initial dose of 100mg in
phase 2 PNH studies (Achillion Press Release, 2017a) (NCT03053102).
The same dose is being administered in the phase 2a proof-of-me-
chanism study in C3G/IC-MPGN trial (NCT03124368, initiated April
2017); initial data from two patients with C3G demonstrated that the
drug significantly inhibited the alternative pathway in vivo, resulting in
elevated intact C3 and decreased levels of the activation fragment Bb.
Importantly, renal function improved (albumin creatinine ratio, ACR)
after 14 days (Achillion Press Release, 2017c). A randomised, placebo-
controlled phase 2 trial (NCT03369236) is now recruiting (posted
ClinicalTrials.gov December 2017) with primary outcome measures of
change from baseline in renal biopsy at 6 months, based on a score
incorporating changes in both the activity index and C3 staining, and
improved renal function. Orphan drug status for C3G was granted by
the FDA in December 2017 and a 12 month open-label proof-of-concept
trial has now been posted (March 2018; NCT03459443) in C3G/IC-
MPGN. Achillion have also announced (December 2017) initiation of
first-in-human studies of their ‘next generation’ FD inhibitor, ACH-
5228, also administered orally and reported to have several-fold im-
proved activity and better PK than ACH-4771 (Achillion Press Release,
2017b). This initial phase 1 trial is a randomised, placebo-controlled,
single ascending dose study of ACH-5228 in healthy volunteers, ap-
proximately 28 subjects are expected to be enrolled to assess safety,
tolerability and to explore PK/PD relationships (Achillion Press Release,
2017d). Novartis also report an orally-bioavailable SM inhibitor of FD
with interesting properties in preclinical testing (Maibaum et al., 2016),
but clinical development has not been reported. Similarly, Ra Pharma
lists a peptide-based inhibitor of FD in their development strategy, this
is currently in preclinical testing with C3G as potential indication
(http://rapharma.com), though further details have yet to emerge
(RaPharma Investor Presentation, 2018).
As mentioned above, a transplanted kidney can be subject to many
assaults from antibody-driven complement activation to I/R injury. A
phase 2 trial being conducted in the UK asks the question whether in-
fusion of the kidney pre-transplant with a drug termed mirococept
(originally APT070), which localises to endothelial membranes and
inhibits the C3 and C5 convertases, will improve renal outcome
(ISRCTN Registry, ISRCTN49958194) (Kassimatis et al., 2017). The
primary endpoint is delayed graft function (DGF), defined as the re-
quirement for dialysis during the first week after transplantation. The
trial was registered in 2012 and has yet to publish data.
2.3. Clinical development of drugs targeting C5, C5a and MAC in renal
disease
Approval for the use of eculizumab for treatment of PNH and aHUS
was a landmark in complement research and anti-complement drug
development (Hillmen et al., 2006). It provided critical clinical vali-
dation that complement could be effectively inhibited in man and save
lives. Two phase 2 trials were conducted in aHUS in 2009 and the re-
sults were remarkable (Legendre et al., 2013). In the first trial patients
with plasma-therapy resistant progressive TMA (measured by low pla-
telet counts), impaired renal function and evidence of hemolysis were
recruited and received eculizumab for 26 weeks; most continued for a
long-term extension phase to 64 weeks (adults, NCT00844545; ado-
lescents, NCT00844844). Seventeen patients were recruited, hemato-
logic values normalised with improved platelet count and improved
renal function. In the second trial 20 patients were recruited who had
long duration of disease and chronic kidney damage and who had re-
ceived prolonged treatment with plasma exchange or infusion but had
no decrease in the platelet count of more than 25% for at least 8 weeks
during PE/PI treatment (adults, NCT00838513; adolescents,
NCT00844428). Twenty were treated for 26 weeks and 19 continued
into the extension phase to 62 weeks. In 16 of the 20 patients, TMA was
inhibited and in the remaining four a transient decrease in platelet
count meant that they did not reach primary endpoint. All 20 patients
came off plasma exchange/infusion and did not require dialysis. In-
tervention early in the disease resulted in greater improvement in
glomerular filtration rate (GFR) in both trials. These remarkable data
from clinical trials of eculizumab in the rare diseases, aHUS and PNH,
together with the discovery in 2005 that complement also contributed
significantly to the etiology of common diseases (such as AMD)
(Edwards et al., 2005; Hageman et al., 2005), drove a vigorous re-
surgence in development of anti-complement therapeutics for multiple
targets and multiple diseases (Morgan and Harris, 2015; Ricklin et al.,
2018).
Many of these molecules are described above and targets lie in the
activation pathways of complement, however, C5 remained, and still is,
a firm favourite as a drug target and various strategies have evolved
since approval of eculizumab to block C5 activity in vivo. One agent,
ravulizumab (ALXN1210), a pH-switched version of eculizumab being
developed by Alexion (www.alexion.com) (Sheridan et al., 2018), is in
phase 3 trials for aHUS (NCT03131219, NCT02949128). This next-
generation version of eculizumab has been engineered in the antigen-
binding region to release the target, C5, at pH6. This results in C5 being
released in the slightly acidic endosome where it is subsequently
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targeted for degradation, whereas the antibody is recycled to the cell
surface devoid of the antigen and available to bind further C5. This ‘pH
switch’, together with engineering of the Fc domain, has resulted in a
drug with improved PK/PD characteristics compared to the original
‘parent’ eculizumab. It is administered every 8 weeks, rather than
fortnightly, with a maintenance dose of 3300mg (in a 60–100 kg adult).
This is higher than that of eculizumab in aHUS (1200mg) although it is
given less frequently. The success with eculizumab in aHUS and PNH
has led to many explorations of its efficacy in other indications, in-
cluding the challenge of kidney transplantation. Eculizumab has been
tested in many clinical trials for DGF and I/R injury. The clinical trial
databases are littered with such trials, frequently investigator-led and
terminated due to poor enrolment. The definitive study of eculizumab
in DGF comes from Alexion’s PROTECT DGF world-wide phase 2/3
registration trial which treated 286 patients and completed in No-
vember 2016 (NCT02145182). The primary outcome measure was in-
cidence of DGF defined as the requirement for dialysis for any reason in
the first seven days post-transplant, and this endpoint was not met. The
trial results have yet to be released but these data are expected im-
minently. The reason for the failure of this trial is not clear, but it
suggests that blockade of C5a and MAC alone are not sufficient to
prevent complement-mediated damage to the kidney, or that other
mechanisms beyond complement play a key role in kidney injury post-
transplant. Disappointing results were obtained in Alexion’s phase 2
trial in AMR of living donor kidney transplant recipients requiring de-
sensitization (NCT01399593); 102 patients were transplanted and re-
ceived eculizumab or standard of care (SOC). The primary endpoint was
treatment failure rate at 9 weeks, but the trial was terminated as sta-
tistical significance was not reached. Study limitations included po-
tential reporting bias with many sites involved, unequal exposure to
randomised prevention therapy between groups, and subsequent
treatment of SOC patients with eculizumab following diagnosis of AMR.
Testing of eculizumab in a small trial for treatment of AMR following
renal transplantation (no desensitisation required; NCT01895127) was
also terminated due to lack of efficacy. Eculizumab continues to be
tested in different indications, some of which are kidney diseases, but to
date no other renal disorder has shown great promise. While success in
aHUS is striking, data remain insufficient to recommend eculizumab as
a first-line agent for the treatment of rapidly progressive C3G (Bomback
et al., 2012; Goodship et al., 2017a, Herlitz et al., 2012). Even in aHUS,
there is debate whether the treatment of this condition requires con-
tinuous anti-C5 therapy or whether an intermittent treatment once
symptoms occur would be sufficient (Sahutoglu et al., 2016). While
such a treatment scheme would be more cost-effective, additional stu-
dies will be required to define which patients may potentially benefit
from this adaptation.
One strategy to overcome high target concentration is to target at
the RNA or DNA level and, indeed, Alnylam Pharmaceuticals have
developed an RNAi, Cemdisiran (ALN-CC5), that is liver-targeted
(through GalNAc conjugation) and blocks hepatic production of C5
(http://www.alnylam.com/). Initial clinical studies demonstrated that
the agent effectively knocked-down circulating C5 by 98% and a single
SC dose of Cemdisiran (600mg) achieved greater than 90% C5 knock-
down six months following administration (Alnylam Press Release,
2016). Whereas these inhibition levels appear to be insufficient to
achieve treatment success with Cemdisiran monotherapy in PNH (see
below), the conditions for such an approach may be more favourable in
the case of aHUS. To this end, a phase 2 clinical trial of Cemdisiran
monotherapy in aHUS was launched late 2017 (NCT03303313), in
which 600mg is administered as monthly SC injection and increase in
platelet count is assessed (Alnylam Press Release, 2017). Given that C5
blockade is required extremely rapidly when an individual presents
with an acute episode of aHUS, and it takes a number of days for C5 to
be supressed with RNAi therapy, it can be speculated that an additional
therapeutic agent may need to be used in the initial stages of therapy to
rescue renal function before C5 levels are subsequently knocked down
using Cemdisiran.
While the blockade of C5 prevents formation of both disease-
causing products, C5a and MAC, the specific interference with any of
these effectors individually may provide further insight into disease
mechanisms and provide clinical benefits in some diseases. This is
particularly true in the case of aHUS, for which it has not been resolved
whether both C5a and MAC act as drivers of the condition. Avacopan is
an orally bioavailable small molecule antagonist of C5aR1, developed
by ChemoCentryx (Bekker et al., 2016; Jayne et al., 2017), which has
progressed to multicentre phase 3 trial in AAV (NCT02994927). Its
potential to induce disease remission at 26 weeks in immunosuppressed
individuals and maintain remission for one year is being compared to
SOC (steroids) and should read out in 2019. Company releases and
conference papers report a decrease in renal inflammation and im-
proved proteinuria in AAV patients treated with avacopan, raising hope
that the agent could improve outcome in renal disease. Indeed, in 2016,
ChemoCentryx reported a case of C3G treated with avacopan with
positive outcome and stabilisation of renal function (Chemocentryx
Press Release, 2016a). The company obtained orphan disease designa-
tion for C3G in 2017 and initiated a multicentre placebo-controlled
phase 2 trial late 2017 (NCT03301467); patients with biopsy-proven
disease and with elevated circulating terminal complement complex
(TCC, also known as sC5b-9) will be assessed for improvement in his-
tologic index following 6 months of twice-daily dosing (30mg/dose)
with avacopan. The focus on orphan disease encompasses further in-
dications including a skin disease (Hidradenitis Suppurativa) and two
further renal indications (Chemocentryx Corporate Presentation, 2018).
A small phase 2 study (NCT02384317) in IgA nephropathy completed
in 2016 and improved proteinuria was reported after 12 weeks
(Chemocentryx Press Release, 2017), and a phase 2 trial in aHUS
commenced in 2015 (NCT02464891). In this trial, six patients were
administered avacopan twice daily (30mg) for two weeks and blood
was taken at various times during that period for analysis of ex vivo pro-
thrombogenic properties on a cultured human microvascular en-
dothelial cell line (presented at the American Society of Nephrology
(ASN) Kidney Week 2016 Annual Meeting (Chemocentryx Press
Release, 2016b)). Although this study supported a role for C5a in
thrombus formation and a potential role for avacopan in therapy, all
patients were on peritoneal dialysis or hemodialysis, treatments which
are in themselves complement-activating; definitive evidence of the in
vivo impact of this agent in aHUS awaits further clinical trials. Recently,
Akari announced that they have initiated phase 2 trials with their C5
inhibitor coversin in aHUS (Akari Press Release, 2018); this tick-derived
protein binds to both C5 and leukotriene B4 and has been clinically
developed for treatment of PNH (see below); further details regarding
the aHUS trial are awaited.
2.4. Clinical development of drugs targeting other pathways in renal disease
The anti-MASP2 monoclonal antibody, OMS721, which blocks the
lectin pathway, has also progressed to phase 3 in renal indications and
has received orphan drug designation for aHUS and IgA nephropathy
(Corporate presentation January 2018). In 2017, Omeros opened an
open-label multi-centre phase 3 trial aiming to recruit 80 adult/ado-
lescent patients with aHUS with increase platelet count as primary
endpoint (NCT03205995). Drug loading is achieved through in-
travenous administration followed by SC maintenance dosing. A phase
2 trial (NCT02682407) in glomerulopathy commenced in 2016 and
recruited patients with C3G, LN, MN and IgA nephropathy. Patient
numbers in the IgA nephropathy arm of the open label phase 2 trial
were limited, but following 12 weeks of treatment, daily steroid use was
reduced or stopped altogether and proteinuria improved. Follow-up
reports in August 2017 indicated that in three out of four patients, the
improved renal function continued to persist post-cessation of dosing.
Omeros has achieved orphan and breakthrough designation of OMS721
in IgA nephropathy and larger, randomised, double-blinded placebo-
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controlled phase 3 trials are expected in 2018. A similar improvement
in tapering of steroids and improved proteinuria was evident in the LN
arm of the phase 2 trial. As the lectin pathway proteins, including
MASP-2, have been shown to exert procoagulant activities (Dobo et al.,
2016), it will be interesting to see whether in some of these indications
the modulation of coagulation pathways contributed to the outcome.
Although C1 esterase inhibitor (C1-INH) has a long-standing history
for the treatment of a non-complement-mediated disease (i.e. heredi-
tary angioedema), the applicability of C1-INH as a possible comple-
ment-targeting therapeutic has gained renewed interest. C1-INH blocks
C1r and C1s of the classical pathway as well as MASPs and complement-
unrelated serine proteases. It is readily available on the market, with
various manufacturers (Pharming, CSL Behring and Shire) providing
different preparations, but has only sparsely been applied in a com-
plement therapeutic context. CSL Behring completed two single centre,
randomised phase 1b/2 trials examining the safety and efficacy of
Berinert in reducing complement-dependent AMR or DGF. The first
(NCT0134510) enrolled 20 patients, finding no severe adverse events or
episodes of AMR during the study period (Vo et al., 2015). The second
(NCT02134314) completed in March 2017, enrolling 70 patients,
looking for improved kidney function after deceased donor kidney
transplantation with high risk of I/R injury and DGF. While results are
expected imminently, CLS Behring initiated a further double-blind,
randomised-withdrawal, placebo-controlled phase 3 study (July 2017)
to evaluate Berinert as add-on therapy to SOC in AMR (NCT03221842).
In the meantime, Shire is recruiting patients for a phase 1 study to study
efficacy of Cinryze, with or without heparin, as a donor pre-treatment
strategy to decrease the incidence of DGF (NCT02435732, started 2015,
last update September 2017). Of note, this presents a different strategy
compared to CSL Behring, as donors of kidney grafts, rather than the
recipients, are treated with Cinryze prior to transplantation, in an effort
to increase graft condition by decreasing complement activity in the
donor.
2.5. Biomarkers and stratification
As disease mechanisms and biological traits predisposing to disease
are becoming clearer, it is increasingly possible to stratify patients for
clinical trial in order to maximise chance of success; getting the ‘right
drug to the right patient’ is critical for effective anti-complement
therapy (Ricklin et al., 2017, 2018). Stratification for clinical trial can
frequently reach beyond clinical phenotype to include other markers
such as genetic variants and protein biomarkers, including complement
activation fragments in plasma and in tissues (Wong et al., 2016).
Plasma biomarkers can provide invaluable mechanistic insight to en-
able subgroups of patients to be identified. For example, elevated TCC
in plasma may be an indicator that C5 is being abnormally and ex-
cessively activated; or presence of C5a, despite blockage of convertase-
mediated C5 cleavage, may be an indicator that other enzymes, such as
thrombin or elastase, are activating C5 (Riedemann et al., 2017). In
these cases, treatment with a C5a-blocker or a C5aR1-blocker, alone or
in combination, might provide additional therapeutic impact. In C3G,
while dysregulation of complement at the level of C3 is evident in most
cases, evidence points to a subset of patients with dysregulation at the
level of C5 (Le Quintrec et al., 2015; Lebreton et al., 2017; Nester and
Smith, 2016); these patients may benefit from anti-C5/C5a therapy (for
example, NCT03301467). Elevated TCC and lowered levels of prop-
erdin may indicate elevated C5 convertase formation and assist iden-
tification of the correct patient subgroup (Corvillo et al., 2016).
Complement biomarkers can also provide an exquisitely sensitive
signal to demonstrate on-target action of a drug enabling rapid proof
that it is having an effect on disease mechanism (Ricklin et al., 2017).
As a first line diagnostic, haemolytic activity of complement in blood
(serum) can be assessed using a number of laboratory assays, including
hemolysis (CH50, AH50) or ELISA-based systems. More informative
biomarkers may read out closer to drug target, for example, it should be
possible to prevent C3 consumption in C3G patients and restore C3
levels to normal range by inhibiting the amplification loop of comple-
ment by one of many different means, whether that be inhibition of FD
or FB, or blockade of C3 cleavage; the read-out should be rapid fol-
lowing drug loading as C3 is constantly synthesised by the liver. Si-
milarly, blockade of C5 will prevent formation of MAC (tissues) and
TCC (soluble) and plasma measurements can rapidly demonstrate that
the drug has bound its target and is having pharmacological impact.
Various clinical trials use complement plasma biomarkers as clinical
trial endpoints (as examples NCT03373461, NCT03124368), and a
growing number use histologic index with a focus on complement de-
position (e.g., NCT03301467).
3. The eye
3.1. Ocular indications involving complement
The eye is a challenging organ to treat due to anatomical barriers
between it and the rest of the body (Fig. 4), never-the-less, common
diseases afflict the eye and rewards, both to health services and to
population health, could be high for a successful therapeutic (Clark and
Bishop, 2018; Mohlin et al., 2017). Complement is implicated in a
number of diseases which afflict the eye (Table 1), but the disease
which particularly caught the attention of the scientific community and
pharmaceutical industry was age-related macular degeneration
(AMD) (Fig. 4c). This is a common blinding disease in the developed
world affecting 1.5% of individuals over 40 years old in the USA; in
white women (of European-descent) aged over 80 the incidence rate
even exceeds 15% (Friedman et al., 2004). Complement turns over
naturally in the eye, just as in most other organs, and is controlled
through the actions of the fluid phase and membrane bound regulators
(Bora et al., 1993; Sohn et al., 2000). This complement turnover, and
the actions of resident phagocytic cells, are critical to maintain an in-
fection-free environment, and the level of therapeutic complement in-
hibition therefore needs to be carefully considered. Moreover, some
changes in chronic eye disorders only progress very slowly and may be
difficult to monitor, therefore often requiring lengthy trials. Despite
such technical challenges, it was AMD with its strong disease link to
complement and high prevalence, which brought complement and anti-
complement therapy back into the limelight around 13 years ago. In
AMD, small deposits comprising protein and lipid start to accumulate
early in the disease process, particularly within the Bruch’s membrane,
the stratified sheet of extracellular matrix which separates the retinal
pigment epithelium, the most posterior element of the retina, from the
choroid (Mohlin et al., 2017). These deposits, termed drusen, disrupt
the health of the retina by interfering with clearance of waste products
and nutrient supply and are characteristic of the early form of the
disease (see Fig. 4). Late stage blinding disease is termed geographic
atrophy (GA or ‘dry’ AMD), characterised by death of the retinal pig-
ment epithelium (RPE) and associated photoreceptors, or neovascular
AMD, characterised by invasion of fragile blood vessels from the
choroid into the retina where leaky vessels cause retinal distortion and
scarring (‘wet’ AMD). Dry AMD currently lacks therapeutic options
whereas wet AMD is treated with anti-VEGF (vascular endothelial
growth factor) injections directly into the eye. It had been known for
some time that drusen were coated with activated complement (Mullins
et al., 2000) but pathogenic consequences were unclear. The discovery
in 2005 of strong associations between AMD disease risk and common
variations in genes encoding proteins of the complement system, par-
ticularly with a common variant in the control protein FH (Tyr402His),
fuelled vigorous research in this area and drove a new era of comple-
ment drug discovery (Gold et al., 2006; Hageman et al., 2005; Haines
et al., 2005; Klein et al., 2005; Ricklin and Lambris, 2007; Spencer
et al., 2008). The exact role of complement in AMD pathogenesis re-
mains unclear. A number of structure/function studies demonstrate that
risk-associated variants of complement proteins produce a more active
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complement system, although this is not the case with FH 402His
(Heurich et al., 2011; Rodriguez de Cordoba et al., 2012; Tortajada
et al., 2013). Elegant structural and functional studies suggest that the
402His form of FH, or its smaller splice product FH-like 1 (FHL1) bind
less well than the 402Tyr variant to structures in the eye, thus poten-
tially providing less protection against chronic inflammation in the eye
(Clark et al., 2010, 2013; Prosser et al., 2007; Weismann et al., 2011).
Interestingly, these studies demonstrate preferential binding of ocular
glycosaminoglycans (GAGs) to the GAG-binding domain in the central
part of FH (in short consensus repeat [SCR] 7) where the 402 variant is
located in FH and FHL1, rather than to the binding domain in the
carboxy terminus in FH, a structural region known to be of critical
importance in protecting the kidney from complement-mediated da-
mage.
In many diseases complement acts to exacerbate rather than drive
pathology, and the following disorders may fall under that umbrella.
Recessive Stargardt macular degeneration (STGD1) is a disease
which has some parallels with AMD, such as lipofuscin accumulation
and complement dysregulation; it is caused by mutations in the gene for
the ABCA4 (ATP binding cassette subfamily A member 4) transporter in
photoreceptor outer segments; patients exhibit buildup of bisretinoid-
containing lipofuscin pigments in the RPE, as there is increased oxi-
dative stress and slow degeneration of photoreceptors. Recent literature
indicates that complement is over-activated in the retina in the mouse
model of disease (Abca4-/- mice), and that gene therapy to provide
additional complement control could directly modulate complement
activation and partially rescue the disease phenotype (Lenis et al.,
2017). Uveitis is inflammation of the uveal tract and can occur at many
sites within the eye; it can be localised to the anterior (iris, anterior
ciliary body), intermediate (vitreous, posterior ciliary body, or ora
serrata) or posterior part of the uvea (choroid, retina) and is a sig-
nificant cause of blindness worldwide. The exact role of complement in
uveitis is unclear, and likely complement has a role as a mediator of an
inflammatory vicious cycle rather than as a driver of disease, but data
from animal models indicate that complement blockade at the level of
C5 may have therapeutic benefit (Copland et al., 2010). Novartis
completed a phase 2 trial with LFG316 anti-C5 in non-infectious in-
termediate-, posterior- or panuveitis (NCT01526889) but data have yet
to be reported. There are other disorders in which complement plays a
role, but to the best of our knowledge anti-complement agents are not
yet being tested in clinical trials; these diseases include glaucoma and
diabetic retinopathy (Mohlin et al., 2017).
3.2. Clinical development of drugs targeting the amplification loop in ocular
disease
Genetic associations with AMD dominate within genes encoding
proteins that activate, inhibit or impact in some way on the
Fig. 4. Structure of the eye and pathogenic mechanisms in AMD. (a) The retina is located towards the posterior of the eye above the choroid; the macula is
responsible for central vision and has the highest density of photoreceptors. (b) In health, the RPE cells, which obtain nutrients from the choroid below, support and
maintain the integrity of the photoreceptor cells; the retina is patrolled by resting microglia. (c) In early AMD (left), deposits known as drusen form within the Bruch’s
membrane; these deposits comprise protein/lipid and cellular debris and are highly complement activating. The Bruch’s membrane becomes thickened, microglia
become activated and accumulate in the sub-retinal space, macrophages are evident in the choroid. In dry AMD (centre), the choroidal blood vessels atrophy and the
RPE cells start to die, leaving photoreceptors without support, this results in confluent areas of atrophy and cell death. In wet AMD (right), choroidal vessels break
through the Bruch’s membrane and become leaky. Activated microglia and macrophage accumulate in the subretinal space, the RPE and immune cells release
proinflammatory mediators and vascular endothelial growth factor (VEGF) setting up a vicious cycle of vessel growth and inflammation, resulting in cell death and
retinal atrophy.
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amplification loop of complement. It is therefore not surprising that
drug discovery and development for AMD has largely focussed in this
area (Fig. 2, Table 1). Two opposing strategies could be employed to
downregulate complement in the eye –supply of additional regulators
or blockade of activators. Presumably the ideal scenario would be one
which modulates complement activation rather than blocks it alto-
gether as blockade could also prevent efficient clearance of debris.
Genentech advanced an inhibitor of FD (lampalizumab) to late stage
clinical testing, but failed to meet primary endpoint in two phase 3
trials (CHROMA and SPECTRI; NCT02247479, NCT02247531;
(Genentech Media Statement, 2017; Roche Media Release, 2017). Post-
hoc analysis of the phase 2 trial (NCT02288559), which studied rate of
growth of retinal atrophy in people with GA due to AMD, demonstrated
that patients carrying a specific genetic variant in a locus close to the
factor I (FI) gene, had 44% decrease in rate of progression over 18
months of treatment when compared to only 20% in the overall study
population (Roche Investor Update, 2013a,b), but the functional or
biological consequences of that SNP were not clear. The phase 3 trials
were identically-designed, double-masked, randomised studies evalu-
ating the efficacy and safety of a 10mg dose of lampalizumab ad-
ministered every four or six weeks by intravitreal injection, versus sham
injections, in more than 1800 participants at more than 275 sites in
over 20 countries (Holz et al., 2018). The primary efficacy endpoint was
evaluated at one year (week 48) and was measured by fundus auto-
fluorescence (FAF) analysis of the GA lesion in the macula. Detailed
analyses demonstrate that in this large study, the FI biomarker had no
effect on outcome (Holz et al., 2018). Despite the setback with lam-
palizumab, FD remains a target of interest in the treatment of AMD. A
new generation of small molecule FD inhibitors as those from Achillion
(ACH-5548), currently in phase 1 in healthy volunteers (Achillion Press
Release, 2017d), and Ra Pharma (preclinical) (RaPharma Investor
Presentation, 2018) may provide much-anticipated insight as to whe-
ther systemic complement inhibition may result in therapeutic benefit
in AMD.
One other agent in trials for GA is APL-2 (by Apellis), this is ex-
pected to start phase 3 trials in the near future. APL-2 was administered
by the intravitreal route in phase 2a studies in GA; this trial, termed
FILLY, investigated outcomes from sham, monthly (15mg) and bi-
monthly (15mg) injections of APL-2 in a total of 246 patients (Apellis
Company Presentation, 2018a,b). Similarly to the lampalizumab trials,
primary efficacy endpoint was change in GA lesion size from baseline to
month 12; patients receiving monthly injections showed a 29% differ-
ence in lesion growth compared to sham injection with the biggest
impact being evident in the second six months of treatment. Following
cessation of treatment and follow-up for a further 6 months, the original
rate of progression of the GA growth resumed. It was noted that in 18%
of the patients receiving APL-2 monthly, there was evidence of new
onset of wet AMD at the 12 month monitoring point, which was higher
than in the sham-treated group. However, it is likely that many of these
patients would have developed wet AMD as part of the natural disease
process as 38% of patients had wet AMD in the fellow (untreated) eye at
the start of the study. It is possible that the exudative events were not
related to ‘fresh’ neovascularisation or were linked to subclinical lesions
missed at baseline, these possibilities warrant further study. It is in-
teresting to note that Apellis launched a small phase 1b/2 open label
trial in wet AMD (NCT03465709; March 2018) with a primary outcome
measurement of safety over 18 months of treatment. It is to be noted
that there were three incidences of endophthalmitis reported in the
FILLY trial, two were culture-positive for Staphylococcus and one cul-
ture-negative. Total blockade of complement within the ocular space
can increase risk of infection, but despite the many complement-tar-
geted trials in AMD to date these numbers have been small. In the case
of APL-2, the risk-benefit profile at 18 months in the FILLY trial sup-
ported progression to phase 3; further study and larger phase 3 trials
(expected to initiate 2018) will indicate whether these adverse events
prove significant. A previous phase 1 clinical trial with the non-
PEGylated derivative (termed POT-4) was carried out by Potentia
Pharmaceuticals in neovascular AMD; this completed in 2010 with a
satisfactory safety profile reported in patients (NCT00473928)
(Biobusiness Briefs, 2009); Potentia Pharmaceuticals was acquired by
the spin out company, Apellis Pharmaceuticals, in 2014. Amyndas lists
plans to initiate clinical development of next-generation compstatin
analogs in AMD (www.amyndas.com/pipeline), yet no phase 1 trial has
been started to date. In addition, Amyndas has a small, engineered
version of FH in preclinical development for AMD (mini-FH; AMY-201).
Although full-length FH has been considered as a FH therapeutic, it is
challenging to purify or produce. Recombinant regulator constructs
such as mini-FH may render the approach of controlling convertase
activity in the eye more feasible (Schmidt et al., 2016).
Ionis Pharmaceuticals have recently announced phase 2 develop-
ment (placebo-controlled, double-masked trial; NCT03446144) of their
antisense agent (ligand conjugated antisense; LICA) targeting comple-
ment FB (FB-LRx). The company aims to enrol 120 participants with GA
secondary to AMD with a single SC dose every other week. Primary
outcome measurement will be percent change in plasma FB, and sec-
ondary outcome measurements include safety and rate of change of the
GA lesion. Phase 1 studies completed in 2017 and achieved dose-de-
pendent reductions in FB and demonstrated a positive safety and tol-
erability profile (Ionis Press Release, 2017). Antisense technology pro-
vides an excellent opportunity to circumvent dosing issues associated
with extremely high levels of protein drug target in the circulation and
potentially provides the means to modulate complement activity rather
than ablate it. Ionis have previously demonstrated that SC administra-
tion of FB antisense to cynomolgus monkeys for 13 weeks at 40mg/kg/
week resulted in dramatic reduction in FB levels in blood and, conse-
quently, in the eye (Grossman et al., 2017); it remains to be seen
whether systemic inhibition of complement can slow or halt progres-
sion of GA.
3.3. Clinical development of drugs targeting C5, C5a and MAC in ocular
disease
Various agents against C5 have been tested in clinical trials for
AMD. Blockade of C5 cleavage stops both C5a and MAC formation, thus
preventing inflammation driven by proinflammatory C5a receptors and
the NLRP3 inflammasome, known to be active in RPE cells in advanced
AMD (Laudisi et al., 2013; Tseng et al., 2013). Eculizumab (described
above) has been administered by intravenous infusion every other week
in a dry AMD phase 2 trial (COMPLETE, NCT00935883); patients were
treated for 6 months and observed for another 6 months. Thirty patients
were enrolled but the rate of GA progression was the same in controls
and eculizumab-treated patients at both 6 and 12 months. However,
there were no drug-related adverse events and none of the eyes con-
verted to wet AMD (Yehoshua et al., 2014). Novartis also tested their
anti-C5 antibody, LFG316, in both dry and wet AMD using intravitreal
administration. In the dry AMD trial (NCT01527500), LFG316 was
administered monthly for 18 months in patients with geographic
atrophy (GA); the trial data are pending in ClinicalTrials.gov but in a
conference proceeding (Angiogenesis, Exudation and Degeneration
Meeting, 2016), the trial was reported to have failed with no difference
in GA lesion growth at month 12. Of note, a 12 month combination trial
of LFG316 together with the anti-properdin antibody CLG561 is on-
going in GA (NCT02515942); properdin is a positive regulator of the
amplification loop and supports surface-associated complement acti-
vation, particularly C5 cleavage; thus, this trial represents a double-hit
on complement amplification and C5 activation. CLG561 is also being
tested (in the same trial) as a monotherapy in GA with potential to
inhibit formation of both the C3 and C5 convertase enzymes. A phase 2
trial of LFG316 in wet AMD completed in 2013 but data have yet to be
reported (NCT01535950).
One other C5 agent, an aptamer (i.e. single strand nucleic acid
‘antibody’) termed Zimura (originally known as ARC1905;
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avacincaptad pegol sodium), is being developed by Ophthotech
(Ophthotech Corporate Presentation, 2018). The company has ongoing
trials in dry AMD (GA) (NCT02686658; phase 2b) and wet AMD
(NCT03374670; phase 2a), in both cases the drug is administered in-
travitreally. The GA trial is randomised, double-masked and sham-
controlled and zimura is given at multiple dose levels every month for
18 months; similarly to the trials described above, the primary efficacy
endpoint is mean rate of change in GA over 12 months measured by
FAF at three time points. Recruitment started in 2016 with the original
goal to treat∼300 patients with GA, with an interim analysis scheduled
at 18 months before further large-scale enrolment. Following release of
the top line data from the phase 3 lampalizumab (Genentech) and the
phase 2 APL-2 (Apellis) trials, Ophthotech announced a modification to
decrease patient numbers and shorten time to primary efficacy end-
point (Ophthotech Press Release, 2017); the top line data should be
available in the second half of 2019. The phase 2a trial in wet AMD
(NCT03362190) commenced October 2017 and should produce top line
data late 2018; Zimura is being administered over 6 months in a dose
ranging study as a combination therapy with anti-VEGF antibody
(0.5 mg Lucentis), an interesting approach given that VEGF blockade is
suggested to decrease expression of complement regulators, such as FH,
in the retina (Keir et al., 2017). Ophthotech is expanding their portfolio
of C5 blockade in ocular conditions by trial of Zimura in STGD1. In this
double-masked sham-controlled phase 2b trial (NCT03364153), pa-
tients will be treated for 18 months; recruitment was announced in
January 2018 and the top line data should read out in 2020
(Ophthotech Press Release, 2018). A similar approach is being taken for
therapy in idiopathic polypoidal choroidal vasculopathy (IPCV); al-
though definitive evidence for a role of complement in IPCV is so far
lacking, it is a disease with clinical features very similar to neovascular
AMD and association with a SNP in FH which affects function (Coscas
et al., 2015; Tanaka et al., 2011). An open label phase 2a safety study
(NCT03374670) started recruitment in March 2018 for combination
therapy of zimura with aflibercept (Eylea), a soluble decoy fusion
protein of VEGF receptor fused to human IgG1; the initial data should
be available towards the end of 2019.
3.4. Biomarkers and stratification
The most prevalent disease of the eye, in which complement plays a
major role, is AMD; while the strongest case can be made for anti-
complement therapy in this indication, it is one of the most con-
founding when considering drug delivery and patient stratification. At
the very least, it should be possible, and probably advisable, to stratify
patients according to their key genetic risk factor, whether it be the
complement genes (‘chromosome 1 disease’), including the FH
Tyr402His variant (rs1061170), or variants at the HTRA1/ARMS2 locus
(‘chromosome 10 disease’) (Kanda et al., 2007; Yang et al., 2006). Data
from the phase 2 trial of lampalizumab in AMD hinted that better
outcome might be obtained in patients stratified for a specific com-
plotype, however, data analysis from the phase 3 trials demonstrated
that outcome was not improved in patients carrying the FI biomarker
(Holz et al., 2018).
Even if it is possible to define a population most likely to have a
significant complement driven disease, questions remain as to the best
route of administration, systemic versus local, and the best part of the
cascade to inhibit, amplification loop alone, C3, or C5 and beyond.
Most therapeutic approaches to date have focussed on intravitreal
blockade of the alternative complement pathway or the amplification
loop. It is of note that whereas the lectin and classical pathways remain
active with blockade of FD or FB, drugs which target both C3 or C5
impact all major activation pathways and MAC formation. It is a matter
of some debate as to whether systemic or local therapy is the best
strategy. Systemic biomarkers of complement activation are present in
AMD patients, although these could be a marker of an active comple-
ment system and a ‘mirror’ of what is happening within the eye, rather
than a consequence of it (Hecker et al., 2010; Reynolds et al., 2009;
Scholl et al., 2008). A follow-up study of liver transplant recipients with
AMD implicated local production of complement, rather than systemic
(originating from liver) as being of greater importance (Khandhadia
et al., 2013). It is clear that the individuals carrying disease-risk com-
plement variants (a risk complotype) have increased levels of comple-
ment deposited in the choriocapillaris and the Bruch’s membrane. It is
also notable that most complement proteins, including FH, do not tra-
verse the Bruch’s membrane, but some, such as FHL-1, C5a and FD are
able to pass through. It remains to be determined whether complement
located on the choroidal side of the Bruch’s membrane, the retinal side,
or indeed, in both locations, contribute significantly to AMD patho-
genesis but evidence to date suggests that complement dysregulation in
early disease is present within the Bruch’s membrane and the chor-
iocapillaris layer (Clark and Bishop, 2018); it might be envisaged that
sub-RPE or choroidal delivery might dampen complement-mediated
inflammation at the relevant site.
As blockade of C3 using APL-2 in phase 2 GA trials (Apellis) de-
monstrated a decrease in the rate of progression of the atrophic lesion,
data from the upcoming large phase 3 trial are eagerly anticipated and
will be highly informative with regards to planning of future clinical
trials in AMD. It is of note, however, that in this phase 2 trial, and also
the MAHALO phase 2 trial with lampalizumab, treatment appeared to
slow disease progression rather than stop or reverse it, and that disease
progressed at the pre-treatment rate once therapy (with APL-2) ceased.
Inhibition of complement in advanced AMD may be of limited benefit,
and the goal must surely be to detect early disease and develop a
therapeutic agent which can significantly halt progression. The cost of
administering intravitreal injections into a large population with signs
of early AMD would be huge and the practicalities unfeasible. Readout
from clinical trials of systemic therapy, with potential to modulate
complement rather than completely ablate, will be significant and in-
formative (such as Ionis FB antisense, upcoming phase 2). Drugs which
provide additional control in the retina rather than ablate activation
may also provide critical insight, these could be based on the naturally
occurring regulators, such as FH, FI, CD46, CD55, and CD59. One such
agent ‘mini FH’ or AMY-201, is under development for AMD (www.
amyndas.com), and a second agent, HMR59 (AAVCAGsCD59; Hemera
Biosciences), is in phase 1 open-label safety trial for delivery of the
MAC inhibitor, CD59, to patients with GA, although little information is
available to date (NCT03144999). Delivery to the retina via gene
therapy is an attractive proposition as administration could be limited
to once in a lifetime (Moore et al., 2017; Naldini, 2015; Ramo et al.,
2008; Schnabolk et al., 2018).
4. The vasculature
4.1. Indications involving the circulatory system driven by complement
Despite intracellular and tissue-located complement activation
gaining increasing attention (Arbore et al., 2017; Hajishengallis et al.,
2017), the blood circulation still remains the major compartment for
complement-mediated immune surveillance and, consequently, com-
plement-related disorders (Ricklin et al., 2016). While complement has
evolved to instantly react to foreign intruders, circulating blood cells
and the vasculature of the host may fall victim to the cascade’s defen-
sive actions, either due to bystander effects or dysregulation of the
activation pathways. Among those are several autoimmune diseases,
some of which have been discussed above due to their major manifes-
tation in the kidneys, and acute-phase disorders related to exposure to
pathogen- or damage-associated molecular pattern as for example
during sepsis, trauma or transplantation (Ricklin et al., 2016). Yet is has
been one of the least prevalent complement-related diseases, parox-
ysmal nocturnal haemoglobinuria (PNH), which has captured at-
tention and fuelled discussions regarding complement-targeted inter-
ventions in the past years (Fig. 5, Table 1).
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In patients suffering from PNH, a variety of events can lead to an
acquired somatic mutation in hematopoietic stem cells (e.g. in the PIGA
gene) rendering them incapable of producing the glycosylpho-
sphatidylinositol (GPI) anchor, which tethers various surface proteins
to the plasma membrane (Hill et al., 2017; Takeda et al., 1993). As a
consequence, PNH patients show clonal populations of blood cells with
a deficiency in membrane regulators, including CD55 and CD59
(Hillmen et al., 1992). Despite their high density in blood and natural
lack of one complement regulator, CD46, healthy erythrocytes are
sufficiently protected from low level opsonisation, such at that which
may occur as bystander deposition during infection. PNH erythrocytes,
however, have a largely reduced capacity for controlling the amplifi-
cation loop (CD55) and MAC formation (CD59). Any encounter with
increased complement activation leaves PNH erythrocytes highly vul-
nerable to (bystander) opsonisation, MAC-mediated membrane damage
and, consequently, intravascular haemolysis (Hill et al., 2017). The
resulting haemolytic anaemia is a defining symptom of PNH, though it
is often the increased risk of developing thrombotic events, due to
reasons not yet fully resolved, that impact morbidity and life ex-
pectancy (10–20 years after diagnosis) most profoundly. For decades,
Fig. 5. Complement-mediated mechanisms of haemolysis in PNH and AIHA. (a) Red blood cells are normally protected from homologous complement attack by
the GPI-anchored cell-surface regulators CD55 and CD59; whereas CD55 controls the C3 and C5 convertases, CD59 prevents MAC formation. In PNH, clones of
hematopoietic stem cells, lacking ability to synthesise and attach GPI anchors, expand in the circulation. These cells do not have CD55 and CD59 on their cell surface
and are thus exquisitely sensitive to direct MAC-mediated lysis (i.e., intravascular haemolysis, IVH). In patients treated with eculizumab (top right), C5 cannot be
cleaved to form C5b and MAC formation is blocked; assuming all C5 is blocked by the drug, this rescues the erythrocytes from IVH and dampens activation of
platelets and other immune cells. However, in the case of total blockade (‘full inhibition’), activated C3 continues to accumulate on the cell surface due to the
deficiency of CD55. This results in a dense array of opsonins accumulating on the membrane, potentially facilitating extravascular haemolysis (EVH) due to
phagocytic uptake. Moreover, ongoing formation of C5 convertases will instantly activate residual free C5 during insufficient blockage, thereby leading to break-
through IVH. Therapeutic blockade at the level of C3 would prevent the coating of opsonins and MAC formation, thus preventing both IVH and EVH. Since generation
of C5 convertases requires a high density of C3b, small amounts of residual free C3 are less likely to induce instant IVH. (b) In AIHA, autoantibodies of the IgA, IgG
and IgM isotypes recognize epitopes on erythrocytes and trigger the classical pathway of complement activation, leading to IVH. Particularly in the case of IgG,
affected erythrocytes are also cleared by non-complement-mediated mechanisms through binding of the immunoglobulins to Fc receptors (FcR) on immune cells. In
some cases, therapeutic complement inhibition may therefore not be fully sufficient to suppress all forms of haemolysis in AIHA. Preventing the formation of
autoantibodies by means of immune suppression may be considered as an alternative approach.
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frequent blood transfusions and, if possible, bone marrow transplan-
tation had been the only treatment options available. And even though
ill-controlled complement activation was linked to the pathogenesis of
PNH very early (Ham and Dingle, 1939), the expected low market (the
estimated incidence rate is 1–10 cases/million/year) and concerns
about therapeutic interference in the complement system prevented the
rapid development of a complement-targeted drug for PNH. For many
patients, the treatment options profoundly improved in 2007, when
Alexion received approval for eculizumab in PNH (NCT00122330). By
blocking convertase-mediated activation of C5, eculizumab prevents
the formation of MAC on PNH erythrocytes, thereby efficiently halting
intravascular haemolysis in most patients. Even during clinical trials, it
became evident that eculizumab treatment could lead to a rapid nor-
malization of haemolytic makers such as lactate dehydrogenase (LDH)
levels (Brodsky et al., 2008; Hillmen et al., 2006; Rother et al., 2007).
Of equal importance, the treatment was generally well-tolerated with
few adverse events, which built confidence in controlling systemic
complement activity therapeutically (Hillmen et al., 2013). There were,
however, reported cases of patients suffering from meningococcal in-
fections, which led to mandatory vaccination before starting treatment.
In the decade since its official availability in the clinic, the risk-benefit
profile has largely been confirmed, and eculizumab has meanwhile
changed the natural history of the disorder (Risitano and Marotta,
2016). Eculizumab treatment is not without drawbacks, however, and
not all patients benefit fully from the treatment. Whereas some rare
cases of non-responders can be pinpointed to a SNP in C5 (p.R885H)
that prevents eculizumab from binding (Nishimura et al., 2014), a third
of patients remain transfusion-dependent despite showing some im-
provement in clinical parameters (Risitano and Marotta, 2018). One of
the potential reasons for this insufficient response is that eculizumab
prevents MAC formation but not opsonization and amplification via the
alternative pathway. This accumulation of C3 opsonins on circulating
PNH erythrocytes, which is well-confirmed experimentally, may have
clinical consequences (Risitano et al., 2009). Firstly, the opsonins (C3b,
iC3b, C3dg) may act as ligands for immune cells and drive the clearance
of PNH erythrocytes by phagocytes; such extravascular haemolysis has
been demonstrated in vitro and in vivo (Fig. 5) (Lin et al., 2015; Risitano
et al., 2009). Moreover, ongoing opsonization gives rise to a steady
presence of C5 convertases; even small transient amounts of non- or
insufficiently blocked C5 may therefore lead to formation of MAC. The
resulting breakthrough haemolysis appears to be most prominent
during episodes of strong complement activity in the circulation
(Harder et al., 2017). Which of the above-mentioned mechanisms pri-
marily contributes to insufficient response to eculizumab, and the re-
sulting transfusion dependence, is not fully resolved and may differ
between patients. New treatment modalities may therefore be critical to
expand the number of PNH patients that fully benefit from comple-
ment-targeted therapy. Finally, and as mentioned above, the treatment
cost of eculizumab is extraordinary high with annual expenses ex-
ceeding $500,000/£340,000 per patient in some markets, and severely
restricting or preventing access to the drug in many countries.
Whereas PNH represents the rare case of blood- and vasculature-
targeted complement disorders without a strong involvement of im-
munoglobulins, many autoimmune diseases cause antibody-induced
complement activation with adverse clinical consequences. For ex-
ample, autoimmune haemolytic anaemias (AIHA) define a class of
blood disorders mediated by the recognition of erythrocytes by auto-
antibodies, which leads to activation of the classical pathway with
subsequent opsonization, amplification and MAC-mediated lysis. AIHA
is an acquired disorder, either idiopathic or secondary to other immune
and nonimmune diseases or treatments, and highly heterogeneous with
various serological forms and clinical presentations (Liebman and
Weitz, 2017). AIHA types have been termed ‘warm’ or ‘cold’ (also re-
ferred to as cold agglutinin disease; CAgD) based on the relative
temperature at which the autoantibodies bind erythrocytes. AIHA can
be IgA, IgG and/or IgM mediated, involving the complement system
depending on the isotype. AIHA is diagnosed based on a positive direct
antiglobulin test (DAT) for either immunoglobulins or C3d, in combi-
nation with haemolytic anaemia. Although DAT tests can be negative
for immunoglobulins, especially in the case of IgM, complement de-
position on erythrocytes can be detected as a footprint for auto-
antibodies (Meulenbroek et al., 2015a,b). AIHA’s are typically treated
by targeting the autoantibody production, through immunosuppression
or rituximab (anti-CD20), but these treatments require some time to
take effect (Barcellini, 2015). Therapeutic interference of complement
activation serves as a more immediate treatment to cover this time
window, as well as a therapeutic option during acute severe exacer-
bations of the disease. Furthermore, complement inhibition might be
beneficial during transfusions, as freshly transfused erythrocytes are
prone to targeting by autoantibodies and destruction by subsequent
complement activation. Similarly to PNH, intravascular haemolysis is
the main symptom of AIHA.
In other autoimmune and antibody-mediated diseases, the effect
of complement activation is focused on the vasculature and/or peripheral
tissue. Antibody-mediated nephritides, such as LN, IgA nephropathy, and
AAV have been mentioned above. Other examples include antipho-
spholipid syndrome, bullous pemphigoid, and multiple sclerosis, and we
refer to specialised literature for additional insight. Myasthenia gravis
(MG) has recently gained particular attention after becoming the third
approved indication for eculizumab treatment. In MG, autoantibodies
target the neuromuscular junctions, resulting in muscle weakness and
fatigue. MG is categorised as either pure ocular MG, affecting the eye
musculature and resulting in ptosis and/or diplopia (∼20%), or gen-
eralised MG, affecting multiple muscles throughout the body (∼80%)
(Hehir and Silvestri, 2018). The majority of MG-related autoantibodies
target the acetylcholine receptor (AChR), which can cause increased
AChR endocytosis. Importantly, the binding of autoantibodies may also
activate complement via the classical pathway, and complement was
implicated in MG pathology as early as the late 1970′s (Sahashi et al.,
1978). The role of complement has been demonstrated in various animal
models (Morgan et al., 2006), and complement blockade protected
against development of experimentally acquired MG (Biesecker and
Gomez, 1989; Hepburn et al., 2008, 2007; Piddlesden et al., 1996; Zhou
et al., 2007). These observations led to several clinical trials exploring the
treatment of generalised MG using complement inhibitors (discussed
below). It is likely that even more autoimmune disorders will move into
the spotlight in the coming years, especially since autoimmunity is not
always recognised as being part of complex pathologies.
Whereas aHUS is the most prominent example of a complement-
driven TMA, it is still not fully resolved which other forms of thrombotic
microangiopathies may involve complement (Meri, 2013; Vieira-
Martins et al., 2016). For example, a contribution of complement in
thrombotic thrombocytopenic purpura (TTP) or Shiga toxin-producing E.
coli-induced HUS remains debated. The strongest body of evidence is
accumulating in the case of haematopoietic stem cell transplantation
(HSCT)-associated TMA (Jodele et al., 2016a). There, it was shown that
patients with proteinuria and elevated sC5b-9 had very poor survival
(<20%) compared to patients with normal levels of these markers
(Jodele et al., 2014). Further studies revealed associations to several al-
terations in complement genes or FH autoantibodies (Jodele et al.,
2016b), and treatment of high-risk patients with eculizumab showed
promising results (see below). The current hypothesis suggests that HSCT-
TMA is not driven by complement, but that endothelial injury due to
transplantation-related stress such as chemotherapy, radiation, surgery or
infection triggers complement activation; in patients with genetic sus-
ceptibility, this insult cannot be sufficiently controlled, thereby leading to
clinical complications and poor survival (Jodele et al., 2016a). Finally,
antibody-mediated complement activation is also a hallmark of solid
organ transplantation-related complications, including hyperacute
rejection due to HLA and/or ABO incompatibility, and in acute-phase
disorders involving the sudden exposure of pathogen- and/or damage-
related molecular patterns such as during sepsis or trauma.
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4.2. Clinical development of complement-targeting drugs in haematological/
vascular diseases
In view of the complement-centred disease mechanism, the con-
firmed therapeutic impact of complement inhibition, and the com-
mercial success of eculizumab in the PNH market, it is not surprising
that many pharmaceutical companies set the initial focus of their de-
velopment programs on this indication (see below) (Morgan and Harris,
2015; Ricklin et al., 2018; Risitano and Marotta, 2018). However, such
an approach is not without risks and has to be considered with care.
PNH is an ultra-rare disease and the patient population remains low,
which impacts both recruitment options and market size. Despite the
limitations discussed above, the existing therapeutic option, i.e. eculi-
zumab and its likely successor ravulizumab, are working well for many
patients and it may be challenging to demonstrate superiority or, at
least, non-inferiority to convince authorities in some cases. Finally,
more than a decade of successful use of eculizumab in PNH has left the
drug firmly established in the clinic and among patient groups, it may
require greater efforts for new players to gain a foothold in the market.
From a clinical and scientific perspective, however, it would be very
much anticipated to have at least one additional complement-targeted
drug available for the treatment of PNH, both to lower cost and improve
treatment access to hitherto excluded markets, and to achieve a better
understanding of optimal intervention points.
Almost 20 complement-targeted drug trials for PNH employing sev-
eral clinical candidates are currently listed in ClinicalTrials.gov as having
active/ongoing status, and many more preclinical lead compounds are in
development for this indication; hence, there is certainly no shortage in
potential options to expand the arsenal of PNH therapeutics (Risitano and
Marotta, 2018). Many of the candidates act on the amplification loop or
on C5 activation and have often also been considered for renal and/or
ocular diseases as discussed above; these will only be briefly covered in
this section, particularly concerning their effect in PNH trials. Candidate
drugs acting at the level of C5 will likely have a comparable mode of
action to eculizumab, athough they may differ in binding site, dose and
PK profile. For example, Alexion’s next-generation antibody ravulizumab
requires less frequent dosing, largely due to FcRn-mediated antibody re-
cycling (see above) (Sheridan et al., 2018). The company recently re-
ported topline results from a phase 3 study in PNH (NCT02946463),
which showed non-inferiority (though not superiority) to eculizumab
with a comparable safety profile (Alexion Press Release, 2018b). In-
travenous infusion of ravulizumab to 125 treatment-naïve patients (single
loading dose and weight-based maintenance dose of 3000–3600mg every
8 weeks) showed similar or slightly better outcome on primary endpoints,
i.e. transfusion avoidance and normalization of LDH levels, with fewer
events of breakthrough haemolysis when compared to the eculizumab
arm. This announcement was subsequently followed with the news that
the eculizumab/ravulizumab switch study in PNH (NCT03056040) was
also considered successful (Alexion Press Release, 2018a). Another C5
antibody (SKY59/RO7112689) with pH-dependent FcRn recycling for
improved PK properties has been developed by Roche and Chugai and is
currently in phase 1/2 trials (NCT03157635). SKY59 binds a distinct
epitope from eculizumab and is thus active in patients carrying the
p.R885H mutation (Fukuzawa et al., 2017). Initial reports from the first
part of the study in healthy volunteers suggest a potential benefit due to
the high subcutaneous bioavailability (∼90%) and long half-life (∼25
days), which may lower the treatment burden; it will be interesting to see
how these properties translate to dose in PNH patients (Roeth et al.,
2017). Other agents targeting C5 are in the clinic, such as the anti-C5
antibody LFG316 from Novartis (phase 2 PNH trial; NCT02534909), and
a Regeneron agent, REGN3918 (phase 1 in healthy volunteers;
NCT03115996), however, no result statements appear to have been re-
leased for these two antibodies. Finally, several companies are gearing up
to produce biosimilar versions of eculizumab itself in anticipation of the
patent protection running out (Ricklin et al., 2018; Risitano and Marotta,
2018).
While antibodies present the dominant species in the field of C5 in-
hibitors, several companies have developed other means of interference at
this level for PNH. For example, coversin (Akari) is currently developed as
a once-daily subcutaneous treatment option for PNH patients. After the 8-
patient, single-arm phase 2 trial (NCT02591862) with daily subcutaneous
dosing achieved its primary endpoint, defined as a reduction in LDH to
≤1.8 times the upper limit of normal (ULN) at day 28, Akari announced
the initiation of phase 3 trials in 2018 (Akari Press Release, 2018). As it
binds to a different epitope than eculizumab, coversin was demonstrated
to be effective in a patient showing resistance to eculizumab (Akari Press
Release, 2016), and phase 2 trials in patients carrying the pR885H
polymorphisms have been initiated (NCT03427060). A version of cov-
ersin with improved PK profile is in preclinical development (Kuhn et al.,
2016). Another protein-based C5 inhibitor, SOBI005 from Swedish Bio-
vitrum, fuses a C5-binding domain with a human IgG1 Fc to improve PK
properties; it is currently in preclinical stages (www.sobi.com/en/Our-
Focus-Areas/Research-and-Development). Whereas the above-mentioned
approaches involve antibodies or small proteins, the strategy employed by
Ra Pharma is based on a macrocyclic peptide. RA101495 binds to a site
on C5 that is distinct from eculizumab and dosing levels make is suitable
for patient self-administration (RaPharma Investor Presentation, 2018).
The peptide has recently been evaluated in two separate 12-week phase 2
dose-finding trials in PNH, one involving eculizumab-treated and treat-
ment-naïve patients (NCT03078582) and one focusing on patients with
insufficient response to eculizumab (NCT03030183). Reported data show
a rapid and sustained reduction of LDH levels and near-complete inhibi-
tion of haemolysis at a daily SC dose of 0.3mg/kg. No major adverse
effects or cases of infection were observed, and SC self-administration was
reviewed favourably. Out of 21 patients, 16 have progressed to the long-
term extension trial (NCT03225287) (Rapharma Press Release, 2018). As
discussed above, Cemdisiran follows a different approach that prevents
hepatic production of C5 rather than inhibiting its activity. Whereas
monotherapy with this RNAi may hold promise in aHUS, treatment with
Cemdisiran alone did not seem to be sufficient in PNH patients. Despite a
high sustained degree of C5 blockade (>90%), LDH levels remained>
1.5 x ULN, indicating that residual levels of C5, e.g. deriving from ex-
trahepatic sources, were sufficient to cause intravascular haemolysis.
Alnylam therefore adopted an approach that combines ALN-CC5 admin-
istration with reduced frequency of eculizumab dosing; interim phase 1
data indicate that a reduced dose of 600 or 900mg eculizumab every 4
weeks (rather than 900mg every 2 weeks) in combination with ALN-CC5
decreased LDH to below 1.5 x ULN, this could potentially represent a
significant cost-saving (Alnylam Press Release, 2016). However, the pri-
cing of Cemdisiran and the advent of ravulizumab will need to be con-
sidered in a final evaluation of the approach. It is clearly evident that
most of the current approaches aim to lower the treatment burden for
PNH patients, both by extending dosing intervals or simplifying admin-
istration routes. None of the current C5-targeted approaches appears to be
suitable for oral administration, although Ra Pharma indicates the pre-
clinical development of an oral C5 inhibitor.
For a chronic disease such as PNH, oral drug administration would
be highly benefiial. When compared to C5-directed therapeutics, some
of the strategies targeting the amplification loop appear to be closer to
that goal. Achillion’s clinical candidate, the small FD inhibitor ACH-
4471, is currently evaluated in several phase 2 trials. These include an
initial three-month trial of ACH-4471 monotherapy (NCT03053102)
followed by a long-term extension trial (NCT03181633) in treatment-
naïve PNH patients. In a separate 6-month study, ACH-4471 is added to
eculizumab therapy in patients that show insufficient response to anti-
C5 treatment itself; oral FD inhibitor doses vary from 100 to 200mg
daily, potentially higher than its dose in aHUS (NCT03472885). Other
FD inhibitors with potential for oral dosing are being developed by
Novartis and Ra Pharma, but no clinical programs appear to be initiated
to date. In contrast to Novartis’ FD inhibitor (Maibaum et al., 2016),
their small molecule FB inhibitor LNP023 has meanwhile entered phase
2 trials for PNH and IgA nephropathy. In the PNH study
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(NCT03439839), patients with insufficient response to eculizumab will
receive a daily oral dose of LNP023 for 13 weeks in addition to ongoing
anti-C5 therapy. Whereas the FD and FB inhibitors will specifically
target the alternative pathway, compstatin analogues will exert a
slightly broader activity by protecting C3 from convertase-mediated
cleavage (Mastellos et al., 2015). The PEGylated APL-2 is being eval-
uated in two phase 1b PNH trials, one as monotherapy in treatment-
naïve patients (NCT02588833) and one as add-on therapy in eculi-
zumab-treated patients showing insufficient response (NCT02264639).
Both studies involve SC administration with daily dosing ranging from
180 to 360mg, although 270mg/day appears to be the standard
dosing. In the add-on study, the four enrolled patients had normalised
LDH values and remained transfusion-independent one year into
treatment; patients with previous high-dose eculizumab could reduce
dosing to normal levels (Apellis Press Release, 2017b). Apellis earlier
reported interim results from the monotherapy study, which led to a
rapid normalization of LDH values to 1.1x ULN with no signs of
breakthrough haemolysis in the three enrolled patients. No severe ad-
verse events had been reported in the two studies (Apellis Press Release,
2017a). Based on the current results, Apellis plans to initiate extension
trials and move directly to phase 3 later in 2018.
With phase 1 trials in healthy volunteers completed, Amyndas also
announced plans for phase 2 trials in PNH and other indications with
their non-PEGylated next-generation compstatin analogue AMY-101
(Amyndas Press Release, 2017). Preclinical PK/PD studies in non-
human primates and using patient PNH erythrocytes indicated high
efficacy of this approach (Risitano et al., 2014). Given the theoretical
benefits of compounds targeting C3 or the amplification loop on op-
sonization and breakthrough haemolysis, it is exciting to see some of
these approaches moving forward in clinical pipelines.
It has to be noted that, even though PNH has gained much attention
over the past few years and has developed into the frontline indication for
complement therapeutics, the disease should not be considered re-
presentative for most complement-mediated disorders. More importantly,
treatment schemes developed for PNH may not, and should not, be di-
rectly translated across indications but adjusted to the pathological me-
chanism and resulting requirements. PNH is rather unique insofar that the
disease is fuelled by the constant presence of highly vulnerable cells in the
circulation, therefore strongly benefiting from continuous complement
inhibition. Any interruption of the treatment will likely lead to a recur-
rence of the symptoms, potentially even a pharmacological rebound effect
due to the presence of pre-opsonised erythrocytes. The strong involve-
ment of the amplification loop is another aspect that has to be considered.
As mentioned above, under C5 blockade the formation of C5 convertases
is not prevented; any C5 that escapes binding by the C5 inhibitor may be
immediately turned into C5b and initiate the formation of MAC. Current
PNH therapy therefore requires constant and complete inhibition and is
vulnerable to breakthrough events. This susceptibility has been shown in
vitro and observed under clinical conditions, as for example during the
clinical trial with Cemdisiran as a monotherapy (see above). The re-
quirement for constant and complete inhibition does not necessarily apply
in other conditions, however. In many cases, it is an imbalance of com-
plement activation and regulation, sometimes undetected over years, that
defines the disease (see above). Even partial inhibition of the activation or
terminal pathways may thus be sufficient to restore homeostasis and re-
solve inflammation. As a consequence, either a titration/adjustment of
required dose ranges or intermittent treatment with careful monitoring of
disease recurrence could be considered. This would reduce the cost and
treatment burden, and further lower the risk of infection. As indicated
before, the choice of target level or combination of treatment options may
further influence the outcome and minimise breakthrough events.
Selecting the ideal point of intervention is particularly important in
the case of haemolytic diseases other than PNH and in autoimmune
disorders. A phase 2 study with eculizumab in CAgD was conducted
some time ago (2011–2015; NCT01303952), and a case report of a
patient receiving 900mg of eculizumab every other week described a
positive outcome for haemolysis and transfusion requirement (Röth
et al., 2015), however, no subsequent studies appear to have been
performed. As mentioned above, blockade at the level of C5 would not
prevent upstream events such as antibody recognition or opsonization.
Importantly, the major and well-defined involvement of a distinct ac-
tivation pathway in antibody-induced disorders opens the door for ra-
ther selective modes of intervention with the potential to interfere
much earlier in pathological events. Indeed, Bioverativ, which has been
acquired by Sanofi in March 2018, is developing a humanised antibody
(BIVV009, originally termed TNT003/TNT009 developed by True
North) that blocks the classical pathway enzyme C1s (Shi et al., 2014).
After receiving orphan designation for CAgD in 2017 and showing
improvement of haemolytic events in a phase 1b study (Panicker et al.,
2013), BIVV009 is currently being evaluated in two parallel phase 3
clinical trials (NCT03347396, NCT03347422) (Bioverativ Press
Release, 2018). Similarly, off-label use of C1-INH (discussed above) is
being evaluated in autoimmune anaemias in open label studies, in-
cluding one case-report where prophylactic administration of C1-INH
was beneficial in an IgM-mediated AIHA patient (Wouters et al., 2013;
Wouters and Zeerleder, 2015). As with the use of C1-INH in kidney
transplants (discussed above), investigations focused on increasing the
survival of the transfused erythrocytes in the patient; haemoglobin and
lactate dehydrogenase levels and C3 deposition on erythrocytes (de-
termined by DAT) were used as markers. Rather than aiming at the
initiation stage, inhibition of C3 activation represents another approach
to prevent opsonisation and haemolysis. For example, in an ex vivo
AIHA model, the C3 inhibitor Cp40 (developed as AMY-101 by
Amyndas) was shown to prevent C3b deposition and intravascular
haemolysis while also reducing extravascular clearance of opsonised
erythrocytes (Baas et al., 2017). APL-2, discussed above, has also
meanwhile entered phase 2 clinical trials for the treatment of AIHA,
including CAgD (NCT03226678).
At least in one autoimmune disease, however, C5-targeted therapy
has shown significant benefit. With MG gaining attention as a com-
plement-mediated disorder, therapeutic studies have focussed on anti-
AChR positive generalised MG. Alexion initiated a pilot phase 2 clinical
trial in August 2008, looking into the applicability of eculizumab in
generalised MG (NCT00727194). The study was terminated early but
enrolled 14 patients, and results indicated eculizumab treatment de-
creased MG severity (Howard et al., 2017). This was followed-up with a
randomised, double-blind, placebo-controlled, multicentre phase 3
clinical trial including 125 patients with refractory generalised MG with
confirmed anti-AChR autoantibodies (NCT01997229). A similar treat-
ment regimen as for aHUS was used. The study finalised in February
2016 and results were published recently (Howard et al., 2017). Results
were positive overall, although no significant difference in the Myas-
thenia Gravis Activities of Daily Living Profile (MG-ADL) score (primary
endpoint) was observed between eculizumab and placebo treated pa-
tients. However, secondary endpoints including other outcome or
quality of life measures did indicate a beneficial effect of eculizumab. In
view of the unmet clinical need, eculizumab was approved by the FDA
for treating patients with generalised MG in October 2017 (Alexion
Press Release, 2017). Ra Pharma has recently (October 2017) initiated a
randomised, double-blind, placebo-controlled, multicentre phase 2 trial
to evaluate its compound RA101495 in generalised MG
(NCT03315130). The study is designed to enrol 36 patients and en-
compasses three arms, comparing SC injections of either 0.1mg/kg or
0.3 mg/kg RA101495 with placebo treatment. Similarly to the eculi-
zumab phase 2 trial, primary outcome is change from baseline in
quantitative MG score, which is a standardised quantitative strength
scoring system. Results are to be expected in 2019.
Finally, the clinical availability of eculizumab has allowed for an
evaluation of the drug in forms of TMA other than aHUS. Whereas
eculizumab was used in case studies of treatment-refractory TTP and in
STEC-HUS during an outbreak in Germany, the impact of the treatment
remains debated and requires larger, controlled studies to confirm a
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potential benefit. In HSCT-associated TMA, earlier studies indicated
that high-risk patients showing elevated levels of sC5b-9 (see above)
could be treated with eculizumab. Even though they could not be
vaccinated against meningitis due to immunosuppression, appropriate
antimicrobial prophylaxis was provided (Jodele et al., 2016c). In an
investigator-led study in 2016, 18 high-risk HSCT-TMA patients were
treated with eculizumab and showed a profoundly improved survival
rate (56%) when compared to high-risk patients from a separate, ob-
servational study who did not receive targeted therapy (9%) (Jodele
et al., 2016d). More recently, a case study of an eculizumab-resistant
patient with HSCT-TMA showed that treatment with coversin had
beneficial effects, even though the patient could not be rescued due to
limited supplies of the drug candidate (Goodship et al., 2017b). Based
on these results, it will be interesting to see whether complement-tar-
geted therapy will develop into a standard treatment for high-risk pa-
tients suffering from HSCT-TMA-related complications.
4.3. Biomarkers and stratification
In contrast to aHUS, C3G and AMD, which are largely driven by
imbalances between the activating and regulating capacities of several
complement components, the diversity and/or impact of genetic al-
terations is typically less pronounced in the haematological and vas-
cular disorders. In PNH, the genetically-induced lack of GPI anchor
synthesis is a common denominator, and the resulting absence of the
GPI-anchored complement regulators CD59 and CD55 on clonal popu-
lations of blood cells is used as a diagnostic marker (Hill et al., 2017).
Moreover, there are additional genetic alterations that have been de-
scribed as influencing the success of eculizumab treatment in PNH
patients. As mentioned above, occurrence of the p.R855H polymorph-
isms leads to complete abrogation of eculizumab binding to C5 due to
changes in the epitope (Nishimura et al., 2014). Whereas this alteration
defines non-responders, a polymorphism in the gene for complement
receptor 1 (CR1, CD35) has been associated with risk of remaining
transfusion-dependent. In a study encompassing 72 PNH patients,
poorly responding patients represented less than 20% of all the H/H
CR1 homozygotes, 33% of all the H/L heterozygotes and 68% of all the
L/L CR1 homozygotes (Rondelli et al., 2014). The molecular details of
this correlation are not yet fully resolved as CR1 is involved in many
biological processes such as immune adherence, the clearance of im-
mune complexes and the degradation of C3-based opsonins (Verschoor
et al., 2016). With the exception of rare cases such as one of the cov-
ersin studies, genetic variations and biomarkers are not typically uti-
lised for patient stratification in PNH trials.
Similarly, few efforts appear to have been applied to select specific
patient populations in trials related to AIHA/CAgD. This may change
based on the insight that cases predominantly involving IgM appear to
be more complement-driven than those dominant in IgG, which seem to
have a stronger contribution of FcγR-mediated clearance (Meulenbroek
et al., 2015a,b).
In MG, the phase 3 trials, which led to the approval of eculizumab
for this indication, only enrolled patients with anti-AChR antibody-
positive generalised MG who had previously failed immunosuppressive
treatment and continued to suffer from significant unresolved disease
symptoms (Alexion Press Release, 2017). This is representative of less
than 10% of all MG patients, although it includes those with the highest
unmet clinical need; it will be interesting to see whether the patient
base will be expanded now that the drug is available for this indication.
5. Conclusion and outlook
During the past three decades, and particularly since the introduc-
tion of eculizumab as the first complement-specific inhibitor into the
clinic more than ten years ago, complement-targeted drug discovery
has seen a remarkable metamorphosis from a “high risk – small market”
status with little interest by major companies to a thriving field
featuring numerous clinical candidates and high commercial interest
(Morgan and Harris, 2015; Ricklin et al., 2018). The realisation that
some of the potential risks associated with the general approach, in
particular the susceptibility to infection, can be mitigated to a sub-
stantial degree by the means of careful target selection, dosing schemes,
tissue-localised application, targeting and/or the involvement of anti-
microbial strategies, built an important base for a newly gained con-
fidence in the therapeutic strategy. In contrast to many other target
areas, therapeutic complement inhibition is not restricted to a specific
indication but may be viewed as a platform approach that will be of
great value for the treatment of a broad range of inflammatory and
degenerative diseases. While bearing great potential, this wide scope of
disorders which involve complement also generates new challenges for
companies entering the field. They face the question whether to strive
for better therapeutic alternatives in established indications (i.e. PNH,
aHUS) or explore new niches, in which the involvement of complement
is not as well defined. As emphasised in this review, complement-tar-
geted drug development has so far been focused on three major in-
dication areas, i.e. renal, ocular, and haemolytic diseases. They are all
related to cells and organs that are in constant close contact with
complement and/or feature ill-protected, and therefore highly suscep-
tible, structures such as the basement membranes of the eyes and the
kidneys. The early commercial and therapeutic success with eculi-
zumab in PNH may have been misleading as the approach may not
easily be translated into other indications. Importantly, however, PNH
is not necessarily representative of most complement-related disorders
(see above). This has emerged as a cautionary tale in the case of AMD,
in which, despite strong genetic disease association, the road to clini-
cally available complement drugs has faced several setbacks, most re-
cently the failure of lampalizumab. The complex anatomy and limited
accessibility of the eye may well require an even more detailed un-
derstanding of tissue-localised disease mechanisms and tailored PK
adjustments to achieve the necessary efficacy. Yet despite the setbacks,
AMD remains a promising indication for complement drugs, and results
from the next stages of clinical trials with C3 inhibitors are eagerly
awaited. Owing to the observation that systemic imbalances in the
complement system, caused by genetic alterations or autoimmune re-
actions, often manifest in the kidneys, renal diseases have quickly
moved into the spotlight of complement-targeted drug development
(Ricklin et al., 2018). Current clinical trials indeed indicate beneficial
effects of therapeutic complement inhibition not only in aHUS but also
in C3G, IgA nephropathy and lupus nephritis. Whereas the small patient
population in these mostly orphan diseases may render the design of
statistically well-powered trials challenging, there appears to be a trend
towards “bucket trials” in which different indications are evaluated at
the same time. Such trials have not only been initiated for kidney dis-
eases and TMAs but also for haematological disorders such as CAgD and
other AIHA’s. Another emerging trend, at least in established indica-
tions such as PNH, is the comparison of monotherapy involving a new
candidate with add-on therapies, in which the drug is administered
alongside eculizumab (e.g. in the case of cemdisiran). To what degree
latter approaches may contribute to higher response rates and/or a
reduction of total treatment cost remains to be explored. Independent of
the indication, the availability of diagnostic tools and disease markers
for patient stratification and therapeutic monitoring will be critical for
advancing the field (Ricklin et al., 2017).
Whereas this review puts a strong emphasis on the three major
therapeutic areas in which complement-targeted drugs are currently
explored, i.e. diseases of the kidneys, eyes, and the vasculature, several
“frontier areas” with high potential for future approaches have been
identified. These include neurological and neurodegenerative disorders
such as amyotrophic lateral sclerosis, Guillain-Barré syndrome, mul-
tiple sclerosis, or Alzheimer’s disease (Brennan et al., 2016; Morgan,
2015), conditions related to mucosal inflammation such as periodontal
disease (Hajishengallis et al., 2016), and autoimmune disorders such as
MG or antiphospholipid syndrome (Thurman et al., 2017). Moreover,
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there is a renewed interest in tackling more complex, acute-phase dis-
orders with strong complement involvement, in particular in-
flammatory complications of transplantation, haemodialysis, trauma or
sepsis (Huber-Lang et al., 2016; Huber-Lang et al., 2018; Reis et al.,
2015). Even in fields such as oncology, in which complement has tra-
ditionally been viewed as being important to keep progression in check,
the focused inhibition of complement components may be considered
alongside targeting of cancer cells with complement-activating anti-
bodies (Reis et al., 2018). There is great hope that with the growing
number of candidates in late-stage clinical trials, the arsenal of com-
plement drugs acting at various point of intervention in the comple-
ment network that are available to clinicians will finally be expanding.
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